

1 **Title:** The 2020 SARS-CoV-2 epidemic in England: key epidemiological drivers and impact  
2 of interventions

3 **Short title:** Epidemiology of SARS-Cov-2 in England

4 **One-sentence summary:** We fit a mathematical model of SARS-CoV-2 transmission to  
5 surveillance data from England, to estimate transmissibility, severity, and the impact of  
6 interventions

7

8 **Authors:** Edward S. Knock<sup>1\*</sup>, Liliith K. Whittles<sup>1\*</sup>, John A. Lees<sup>1\*</sup>, Pablo N. Perez-Guzman<sup>1\*</sup>,  
9 Robert Verity<sup>1</sup>, Richard G. FitzJohn<sup>1</sup>, Katy AM Gaythorpe<sup>1</sup>, Natsuko Imai<sup>1</sup>, Wes Hinsley<sup>1</sup>,  
10 Lucy C. Okell<sup>1</sup>, Alicia Rosello<sup>4</sup>, Nikolas Kantas<sup>5</sup>, Caroline E. Walters<sup>1</sup>, Sangeeta Bhatia<sup>1</sup>,  
11 Oliver J Watson<sup>1</sup>, Charlie Whittaker<sup>1</sup>, Lorenzo Cattarino<sup>1</sup>, Adhiratha Boonyasiri<sup>3</sup>, Bimandra  
12 A. Djaafara<sup>1</sup>, Keith Fraser<sup>1</sup>, Han Fu<sup>1</sup>, Haowei Wang<sup>1</sup>, Xiaoyue Xi<sup>5</sup>, Christl A. Donnelly<sup>1,6</sup>, Elita  
13 Jauneikaite<sup>1</sup>, Daniel J. Laydon<sup>1</sup>, Peter J White<sup>1,2</sup>, Azra C. Ghani<sup>1</sup>, Neil M. Ferguson<sup>1^</sup>, Anne  
14 Cori<sup>1^</sup>, Marc Baguelin<sup>1,4</sup>

15

16 **Affiliations:** 1. MRC Centre for Global Infectious Disease Analysis, Abdul Latif Jameel  
17 Institute for Disease and Emergency Analytics (J-IDEA), School of Public Health, Imperial  
18 College London; UK. 2. National Institute for Health Research Health Protection Research  
19 Unit in Modelling and Health Economics, UK; 3. Department of Infectious Disease, School of  
20 Public Health, Imperial College London; UK; 4. Department of Infectious Disease  
21 Epidemiology, Faculty of Epidemiology and Population Health, London School of Hygiene  
22 and Tropical Medicine, London, UK; 5. Faculty of Natural Sciences, Department of  
23 Mathematics, Imperial College London, UK; 6. Department of Statistics, University of Oxford,  
24 Oxford, UK

25

26 **Correspondence:** m.baguelin@imperial.ac.uk, neil.ferguson@imperial.ac.uk

27 \*Equal contribution, ^Equal contribution

28 **Main text: 3728 words**

29 **Abstract** (125 words)

30 We fitted a model of SARS-CoV-2 transmission in care homes and the community  
31 to regional surveillance data for England. Among control measures implemented, only  
32 national lockdown brought the reproduction number below 1 consistently; introduced one  
33 week earlier it could have reduced first wave deaths from 36,700 to 15,700 (95%CrI: 8,900–  
34 26,800). Improved clinical care reduced the infection fatality ratio from 1.25% (95%CrI:  
35 1.18%–1.33%) to 0.77% (95%CrI: 0.71%–0.84%). The infection fatality ratio was higher  
36 in the elderly residing in care homes (35.9%, 95%CrI: 29.1%–43.4%) than those residing in  
37 the community (10.4%, 95%CrI: 9.1%–11.5%). England is still far from herd immunity, with  
38 regional cumulative infection incidence to 1st December 2020 between 4.8% (95%CrI:  
39 4.4%–5.1%) and 15.4% (95%CrI: 14.9%–15.9%) of the population.

40

## 41 **1 Introduction**

42 England is among the countries worst-affected by the global pandemic of COVID-19, caused  
43 by the novel *Betacoronavirus* SARS-CoV-2. As of 2<sup>nd</sup> December 2020, over 51,000 deaths  
44 have been reported nationally, or 91 deaths per 100,000 people (1). The impact of the  
45 epidemic has varied across the country, with regional epidemics differing in their severity  
46 and timing. A key feature in all regions is the burden suffered by older adults living in care  
47 homes, where mortality has been high.

48

49 We use a mathematical model of SARS-CoV-2 transmission to reproduce the first two  
50 waves of the epidemic across England's seven NHS regions and assess the impact of  
51 interventions implemented by the UK government. We analyse the epidemic from  
52 importation of SARS-CoV-2 into each region to the 2<sup>nd</sup> December 2020: encompassing the  
53 first national lockdown from March – May, the interventions implemented as COVID-19

54 deaths increased again in the autumn, eventually leading to the second national lockdown in  
55 November.

56

57 We built an age-structured stochastic transmission model of SARS-CoV-2, representing care  
58 homes, hospital clinical pathways and the wider community (Materials and Methods). We  
59 developed a Bayesian evidence-synthesis approach to estimate model parameters and to  
60 reconstruct regional epidemics using data from daily recorded deaths, PCR testing, hospital  
61 admissions, hospital bed occupancy, individual patient outcomes, contact surveys, and  
62 serological surveys. We evaluated temporal changes in transmission as new control  
63 measures were implemented and then relaxed, and population immunity accrued. Inclusion  
64 of serological data allowed us to robustly estimate region- and age-specific disease severity,  
65 to compare severity in care home residents to elderly individuals in the community, and  
66 estimate the total epidemic size, by calculating the proportion of individuals infected over  
67 time in each region. Finally, we examined counterfactual epidemic scenarios, varying the  
68 date and duration of the first national lockdown and the effectiveness of restricting care  
69 home visits, to quantify the resulting impact on mortality.

70

71 Our analysis, which synthesises multiple data sources and parametrically accounts for their  
72 biases, provides a comprehensive overview of transmission, hospitalisation, and mortality  
73 patterns of SARS-CoV-2 in the first and second waves (up to 2<sup>nd</sup> December) in all regions of  
74 England. Our results provide crucial insights for controlling the epidemic in the future,  
75 emphasising the importance of acting fast to save lives.

76

## 77 **2 Results**


### 78 *2.1 Epidemic trajectory*

79

80 We used our evidence-synthesis approach, to infer the COVID-19 epidemic start date in  
81 each NHS England region (Figure 1A), then reconstructed epidemic trajectories for  
82 hospitalisations (Figure S7) and deaths in care homes and hospitals (Figure 1B-H). We  
83 estimated the basic reproduction number,  $R_0$ , defined as the expected number of onward  
84 infections from an infectious individual in a fully susceptible population to be 2.9 (95% CrI:  
85 2.8-3.1) nationally. Figure 1I shows how the effective reproduction number  $R_t^{eff}$  (the  
86 expected number of onward infections from an individual infected at time  $t$ ) changed in each  
87 region over time, in relation to government control measures and accrual of population  
88 immunity.

89 The first COVID-19 death in England occurred on 5<sup>th</sup> March 2020 (2). Seven days later, in  
90 response to the growing epidemic, the government began to introduce control measures,  
91 initially requiring individuals with a dry persistent cough and/or fever to self-isolate (3). On  
92 23<sup>rd</sup> March this escalated to a full national lockdown (4, 5). Irrespective of initial differences,  
93 the level of transmission during lockdown was similar across all regions (Figure 1I),  
94 consistent with mobility data showing movement during lockdown reduced to a consistent  
95 level nationally (6).

96



97

98 *Figure 1: Trajectory of the England COVID-19 epidemic. A, The inferred epidemic start date in each*  
 99 *NHS England region. B-H, The model fit to reported daily deaths from COVID-19 in care homes and*  
 100 *hospitals for each NHS England region. The points show the daily data, solid lines the median*  
 101 *posterior and the shaded area shows the 95% CrI. I, The mean effective reproduction number within*  
 102 *the general community (i.e. excluding care homes) in each region from March to December. Vertical*  
 103 *lines and labels represent dates of key policy changes, defining the breaking points of the underlying*  
 104 *piecewise linear transmission rate. Dashed horizontal line depicts reproduction number of 1.*

105

106 The epidemic in London began 15 days before (95% CrI: 28 days before, 3 days after) the  
 107 rest of the country (Figure 1A), meaning the lockdown occurred at a later stage of its  
 108 epidemic. London experienced a mortality of 88.5 (95% CrI: 79.9–95.3) per 100,000 during  
 109 the first wave, compared to the national average of 70.7 (95% CrI: 64.6–77.1), despite

110 having a younger population and a smaller care home population than other regions (296 vs  
111 603 per 100,000 nationally).

112


113 A key feature of the first epidemic wave in England, in common with other European  
114 countries, was the high death toll within care homes, which accounted for 22.6% laboratory-  
115 confirmed COVID-19 deaths in England as of 1<sup>st</sup> August 2020. Although community  
116 transmission rates fell during lockdown, transmission within care homes continued to rise,  
117 with infection risk peaking in care home residents, between 26<sup>th</sup> March in London and 12<sup>th</sup>  
118 April in North East and Yorkshire (Figure 2A). Deaths in care homes peaked on average 13  
119 days later than hospital deaths (Figure 1B-H).

120

121

122

123



124

125 *Figure 2: A, Inferred daily SARS-CoV-2 infections in England care home residents (right axis) and the*  
 126 *wider community (left axis). B-H, Comparison of modelled (shaded bands) and observed (solid line)*  
 127 *proportion of PCR tests that are positive, under pillar-2 testing (community swab testing for symptomatic*  
 128 *individuals) in >25 year olds. Shaded bands depict 95% CrI, 50% CrI and median model outputs.*

129

130 The first lockdown in England continued until 11<sup>th</sup> May, when people unable to work remotely  
 131 were permitted to resume their jobs. Over the summer restrictions were successively eased,  
 132 with non-essential shops, pubs and restaurants opening, followed by the government's 'Eat  
 133 Out to Help Out' restaurant subsidy scheme in August (7). This led to a steady increase in  
 134 transmission, with  $R_t^{eff}$  rising above 1 in all regions by mid-August (Figure 11).

135

136 Increasing PCR test positivity marked the beginning of a second epidemic wave (Figure 2B-  
137 H, S6). The accompanying introduction of non-pharmaceutical interventions (NPIs) began  
138 with the “Rule of Six” (limiting social gatherings to 6 persons maximum) on 14<sup>th</sup> September  
139 (8), followed by the localised tiered restrictions on 14<sup>th</sup> October (9). These measures limited  
140 transmission in most regions but were not sufficient to reduce  $R_t^{eff}$  below 1 (Figure 11).  
141 Consequently, on 31<sup>st</sup> October, the government announced a second national lockdown,  
142 which lasted from 5<sup>th</sup> November to 1<sup>st</sup> December (10).

143

144 Restrictions during the second lockdown were less stringent than the first, with schools and  
145 some workplaces remaining open. This was reflected in  $R_t^{eff}$  estimates of 0.83 (95% CrI:  
146 0.81–0.85) at the start of the second lockdown, compared to  $R_t^{eff} = 0.54$  (95% CrI: 0.50–  
147 0.59) at the start of the first. We estimate that without the population immunity accrued  
148 during the first wave, contact rates during the second lockdown would have resulted in a  
149 reproduction number of  $R_t = 0.95$  (95% CrI: 0.93–0.98). Hence, population immunity helped  
150 to reduce transmission further below the critical threshold of  $R_t^{eff} = 1$ .

151

## 152 *2.2 Severity and hospitalisation*

153

154 COVID-19 manifests a broad spectrum of severity, from asymptomatic infection to life-  
155 threatening illness requiring intensive care. We estimated age-patterns of clinical  
156 progression in people admitted to hospital using individual-level data from 17,702 patients  
157 admitted between 18<sup>th</sup> March and 31<sup>st</sup> May 2020 (inclusive) in the COVID-19 Hospitalisation  
158 in England Surveillance System (CHESS, (11)) (Materials and Methods). We derived  
159 estimates of the time spent in each stage of the hospital pathway (including general wards,  
160 ICU and post-ICU stepdown care), as well as age-stratified probabilities of progression  
161 through that pathway (Figure 3 and Figure S8). We accounted for differing length of stays  
162 given different outcomes; there were marked differences in average length of ICU stay for



163 those who died in ICU, those who later died in stepdown care and those who were  
164 discharged following stepdown care (Figure 3F). Among patients over 65, we found the  
165 probability of admission to ICU decreased with increasing age. Severity of COVID-19  
166 increases with age, but for older patients and those with most severe illness, the benefit of  
167 ICU admission, ventilation and the corresponding prognosis may not be better than with  
168 oxygen therapy in a general ward (12). Thus, older and more severely infected patients may  
169 be directed to care on a general ward rather than admitted to ICU.


170

171 We used estimates of clinical progression to parametrise the transmission model, enabling  
172 us to infer temporal and regional differences in disease severity, informed by local  
173 demography, observed daily hospital admissions, bed occupancy and deaths. We measured  
174 severity of disease by the infection fatality ratio (IFR) and the infection hospitalisation ratio  
175 (IHR).

176

177

### Patient progression in hospital




178

179 *Figure 3: Age-dependent probabilities of progression through hospital pathways. A, Probability of*  
 180 *admission to ICU. B, Probability of death in a general ward. C, Probability of death in ICU. D,*  
 181 *Probability of death in stepdown care. E, Probability of death through all hospital pathways. Black*  
 182 *circles and vertical segments show posterior mean and 95% credible intervals of splines fitted to data,*  
 183 *blue circles and vertical segments show raw mean values and 95% confidence intervals (exact*  
 184 *binomial) for each 5-year age group. F, Average length of stay in each ward (posterior mean and 95%*  
 185 *credible intervals).*

186

187 The severity of disease increased with age in all regions with the steepest increase above  
 188 65 years (Figure 4A-C), in line with observations worldwide (5). Regional estimates of age-  
 189 aggregated disease severity depend on the population age distribution, which is similar in  
 190 most regions of the country, except London, where the median age is 34.6 years (vs 39.5  
 191 years nationally). At the start of the first wave, London experienced an IFR (respectively  
 192 IHR) of 0.91% (95% CrI: 0.82%–1.00%) (resp. 3.02%; 95% CrI: 2.82%–3.19%) compared to  
 193 the national average of 1.25% (95% CrI: 1.18%–1.33%) (resp. 3.52%; 95% CrI: 3.29%–  
 194 3.72%) (Figure 4D-E).



195

196

197

198

199

200

201

202

203

204

205

206

207

208

209

210

*Figure 4: Relative severity of disease by age group and region. **A**, and **B**, Variation in the Infection fatality ratio (IFR) and Infection Hospitalisation Ratio (IHR) by age group in each region. Ages 80+ were modelled as a single risk group, care home residents are not included. **C**, The England IFR and IHR by age group and in care home residents (estimates denoted CHR at the right-hand side of the panel). National severity estimates are produced by aggregating regional estimates based on infection incidence. **D**, The regional IHR, aggregated over age and risk group by infection incidence. Plots a-d use parameter estimates, and incidence weightings calculated as of 1<sup>st</sup> December 2020. **E**, The England IFR over time, coloured dots show regional estimates of IFR at the start of the epidemic and on 1<sup>st</sup> December 2020 (clusters each correspond to one time-point, LON: London). In plots **C-E** Shaded bands depict 95% CrI and interquartile ranges, points depict medians.*

Regional variation in the population age distribution did not fully account for differences in severity, with London still experiencing lower mortality when stratified by age (Figure 4A-B). The oldest age group (80+) in London had an IFR of 6.1% (95% CrI: 5.2%–6.8%) compared to 12.7% (95% CrI: 10.8%–14.3%) in the North West.

211 We estimated temporal trends in the IFR for England, by weighting regional estimates by  
212 incidence and population demographics. At the start of the first wave, the national IFR was  
213 1.25% (95% CrI: 1.18%–1.33%) (Figure 4E), consistent with earlier reports from serology  
214 data alone (13). The national IFR initially appeared to increase, as transmission widened  
215 from London to regions with older populations and greater disease severity. Over the first  
216 wave, the proportion of hospital admissions resulting in death decreased, due to  
217 improvements in clinical management and alleviation of capacity constraints (14), leading to  
218 a national IFR of 0.77% (95% CrI: 0.71%–0.84%) by the end of the first wave. The  
219 magnitude of the relative reduction in IFR over time varied between regions, from 36.5%  
220 (95% CrI: 26.5%–47.5%) in the North West to 64.6% (95% CrI: 58.6%–68.8%) in London.

221

222 The IFR was greater among care home residents (35.9%, 95% CrI: 29.1%–43.4%) than in  
223 the 80+ in the community (10.4%, 95% CrI: 9.1%–11.5%, Figure 4C). Many care home  
224 residents did not transfer into hospital, and instead died in the facilities where they lived, so  
225 conversely the IHR was lower in care home residents (19.1%, 95% CrI: 11.5%–26.8%) than  
226 in those aged 80+ in the community (51.1%, 95% CrI: 47.6%–54.3%). We present national  
227 estimates of severity at the end of the second wave, stratified by age and care home  
228 residency in Table S9.


229

### 230 *2.3 Epidemic size*

231

232 Data from repeated serological surveys of blood donors aged 15-65 informed our estimation  
233 of the total regional epidemic size (Figure 5A-G), accounting for imperfect sensitivity and  
234 specificity of serological tests (Materials and Methods) (15). The cumulative proportion of the  
235 population ever infected with SARS-CoV-2 ranged from 4.8% (95% CrI: 4.4%–5.1%) in the  
236 South West to 15.4% (95% CrI: 14.9%–15.9%) in London (Figure 5H). Predicted  
237 seropositivity was initially greater than cumulative incidence, due to imperfect test specificity.

238 The increase in seropositivity lagged cumulative infections by two weeks, reflecting the time  
 239 from infection to seroconversion.  
 240



241  
 242 *Figure 5: Cumulative incidence and seropositivity by region. A-G, Comparison of the estimated*  
 243 *proportion of the population testing seropositive with observations from serological surveys. Vertical*  
 244 *grey shaded bands show serological survey timings, black points the observed seroprevalence (bars:*  
 245 *95% exact confidence intervals), blue and purple lines show estimated proportion of the population*  
 246 *infected and seropositive respectively (shaded bands the 95% CrI, 50% CrI and median). H,*  
 247 *Comparison by region of the estimated cumulative attack rate in care home residents vs in the 80+*  
 248 *age group in the community (median, 95% CrI). The final epidemic size in each England NHS region*  
 249 *I) in total and J) in care home residents.*


250  
 251 Seropositivity notably declined following the first wave in some regions (Figure 5A-G). This  
 252 may reflect antibody waning (16), or temporal trends in the composition of the surveyed  
 253 population. Lockdown restrictions made attending blood donation centres difficult for all  
 254 except key workers, who were more likely to have been infected (17), and may therefore be  
 255 overrepresented in the sample of blood donors during the two lockdowns.

256 The proportion of care home residents ever infected with SARS-CoV-2 was 13.7% (95% CrI:  
 257 10.7%–16.7%), much higher than the 4.2% (95% CrI: 4.0%–4.4%) estimated in >80-year  
 258 olds living in the community. This difference was consistently observed across all regions  
 259 (Figure 5H). Regional differences in care home attack rates mirrored the patterns seen in the  
 260 general community, with regions with larger community epidemics also experiencing larger  
 261 care home epidemics (Figure 5I,J).

262

### 263 2.4 Impact of non-pharmaceutical interventions (NPIs)

264 We explored counterfactual intervention scenarios and examined the potential impact on  
 265 mortality of initiating the first national lockdown one week earlier or later; ending that  
 266 lockdown two weeks earlier or later; and 50% more or less restricted care home visits  
 267 throughout the epidemic (Figure 6).



268

269 *Figure 6: Counterfactual analysis of the impact on mortality aggregated across NHS England*  
 270 *regions of A, D, initiating lockdown one week earlier / later, B, E Relaxing lockdown two*  
 271 *weeks earlier / later, and C, F 50% more / less restricted care home visits. Panels A, B, D*  
 272 *and E all present counterfactual outcomes for daily deaths in England but have different y-*  
 273 *axis scales to better highlight differences between the observed data and each alternative*  
 274 *lockdown scenario.*

275

276 The timing of the initial national lockdown was crucial in determining the eventual epidemic  
277 size in England. Locking down a week earlier could have reduced the first wave death toll  
278 (up to 1<sup>st</sup> July 2020) from 36,700 to 15,700 (95% CrI: 8,900–26,800) while delaying  
279 lockdown by a week would have increased the deaths to 102,600 (95% CrI: 66,400–  
280 154,800) (Figure 6A, D). The impact varied by region, with regions with less established  
281 epidemics at the time of the first lockdown more sensitive to the timing of the intervention  
282 (Figure S10). Locking down a week later may have increased deaths, with large variability  
283 by region, from 105% in London to 274% in the Midlands but with very large uncertainty  
284 (Figure S9). Initiating a lockdown to interrupt the exponential growth phase of an epidemic  
285 has a much greater impact on reducing total mortality than extending an existing lockdown.  
286 Due to this asymmetry, relaxing the lockdown measures two weeks earlier (respectively  
287 later), could have increased deaths by 9,300 (95% CrI: 700–17,000) (respectively prevented  
288 9,800 (95% CrI: 7,400–12,100) deaths) prior to 2<sup>nd</sup> December (Figure 6B, D).

289

290 We also explored counterfactual scenarios varying the level of visit restriction in care homes  
291 and estimated that reducing contact between the general population and care home  
292 residents by 50% could have reduced care home deaths by 44% (95% CrI: 17%–64%)  
293 (Figure 6C).

294

### 295 **3 Discussion**

296

297 We present a comprehensive overview of SARS-CoV-2 transmission, hospitalisation,  
298 mortality and intervention impact in the first two epidemic waves across all regions of  
299 England between March and December 2020. We successfully reproduce the transmission  
300 dynamics of the two epidemic waves, in terms of cases, PCR prevalence, seroprevalence,  
301 hospitalised cases (general wards and ICU), and deaths in hospitals and in care homes.

302

303 We estimate intense transmission in care homes even during the first national lockdown  
304 when  $R_t^{eff}$  in the community was well below one in all regions (Figure 2) (18–20). Combined  
305 with our counterfactual analysis of restricting visits (Figure 6) this suggests that reducing  
306 infection levels in care home residents is challenging. This highlights the difficulty of  
307 protecting care home residents from COVID-19: due to the necessarily close contact  
308 between staff and residents within a care home, once a care home outbreak has begun it is  
309 very difficult to reduce transmission, which overrides any impact of reducing the number of  
310 introductions (21, 22).

311

312 We find that, consistent with existing literature (23), disease severity increases with age.  
313 Assessment of severity is complicated by the broad clinical spectrum of COVID-19 (24–26)  
314 hence, recent published estimates are still based on data from early in the pandemic (27).  
315 Here we provide updated severity estimates based on multiple contemporary data streams.  
316 We estimate considerable regional heterogeneity in severity, broadly consistent in the  
317 general population and in care homes for IFR and IHR. London experienced the lowest  
318 severity even after adjusting for its younger population. The estimated two-fold reduction  
319 over time in IFR (Figure 4) cannot be explained solely by the introduction of dexamethasone  
320 which reduces mortality amongst ICU patients (28), but rather a combination of factors  
321 including improvements in clinical management, greater experience in treating patients in  
322 ICU, and alleviation of capacity constraints (14, 29).

323

324 Our analysis shows large regional variation in burden, especially in the first wave. This is  
325 likely due to the pattern of seeding and the timing of lockdown relative to how advanced  
326 each region's epidemic was (Figure 1A). Our counterfactual scenarios of initiating the first  
327 national lockdown one week earlier or later highlight the importance of early interventions to  
328 reduce overall mortality (Figure 6).



329

330 The extent and duration of infection-induced immunity to SARS-CoV-2 and its relationship to  
331 seropositivity remains unclear. Related seasonal coronaviruses induce immunity that wanes  
332 in one or two years (30), though antibody titres following SARS-CoV-1 infection appear to  
333 decay more slowly (31). Our estimated cumulative incidence over time (Figure 5), strongly  
334 supports the hypothesis that the epidemic decline after the first national lockdown was due  
335 to NPIs, with immunity playing a minimal role (32). Population-level immunity was insufficient  
336 to prevent a second wave of infection in any region (Figure 1), illustrated by the increase in  
337 reported cases and deaths which prompted the second national lockdown (33).

338

339 With the authorisation of the first SARS-CoV-2 vaccines in December 2020, we are now  
340 entering a new phase in the control of the COVID-19 pandemic. However, our estimates of  
341 current population immunity are low, with regional cumulative attack rates ranging from 4.8%  
342 to 15.4%, therefore any vaccination campaign will need to achieve high coverage and high  
343 levels of protection in vaccinated individuals to allow NPIs to be lifted without a resurgence  
344 of transmission. While vaccinating the most vulnerable age and risk groups will considerably  
345 reduce the burden of COVID-19, a large proportion of younger age groups may also need to  
346 be vaccinated to reach the immunity threshold for control. Our high estimates of  
347 transmission in care homes imply that vaccine uptake there will need to be especially high,  
348 particularly if vaccine efficacy is lower amongst older age groups.

349

350 We make a number of simplifying assumptions in our analysis. First, due to the  
351 compartmental nature of our model, we do not explicitly model individual care homes, rather  
352 the regional care home sector as a whole. However, as care home workers may work across  
353 multiple facilities leading to within and between care home transmission, we do not expect  
354 the simplification to substantially affect our conclusions. Similarly, we do not model individual  
355 households or transmission within and between them. When assessing the impact of NPIs

356 on transmission we therefore capture population averages, rather than the contribution of  
357 household and non-household contacts. Second, hospital-acquired infections may have  
358 contributed to overall transmission, especially around the peak of the epidemic, and to  
359 persistence of infection in England over the summer months (34, 35). Our model does not  
360 explicitly represent nosocomial transmission; therefore such effects will be encompassed  
361 within our regional  $R_t^{eff}$  estimates. Third, each data stream was subject to competing biases,  
362 which we statistically accounted for as far as possible (supplement section 1.1.2). A key  
363 strength of our evidence-synthesis approach is that we do not rely on any single data  
364 source, combining multiple perspectives to provide a robust overall picture of the epidemic.  
365 Finally, we model the epidemics in each NHS region in England independently without  
366 accounting for spatial effects across regional boundaries, or spatial heterogeneity within  
367 regions. This spatial scale was determined by the data and reflects limited movement  
368 between regions due to travel restrictions but does allow for movement within regions.  
369  
370 Our analysis provides a comprehensive overview of transmission, hospitalisation, and  
371 mortality patterns of COVID-19 in the first and second waves of the epidemic in all regions of  
372 England, one of the countries worst-affected by the pandemic. Integration of multiple data  
373 streams into a single cohesive modelling framework, enables us to disentangle transmission  
374 and severity from features of the surveillance system and provide robust estimates of the  
375 epidemiological characteristics of the COVID-19 epidemic in England. As nationwide  
376 vaccination programmes are rolled out, our results will help to inform how NPIs are applied  
377 in the future.  
378

379 **References**

380

- 381 1. GOV.UK, Coronavirus (COVID-19) in the UK (2020), (available at  
382 <https://coronavirus.data.gov.uk/details/download>).
- 383 2. E. Mahase, Covid-19: UK records first death, as world's cases exceed 100 000. *BMJ*.  
384 **368** (2020), doi:10.1136/bmj.m943.
- 385 3. GOV.UK, Prime Minister's statement on coronavirus (COVID-19): 12 March 2020 -  
386 GOV.UK, (available at [https://www.gov.uk/government/speeches/pm-statement-on-](https://www.gov.uk/government/speeches/pm-statement-on-coronavirus-12-march-2020)  
387 [coronavirus-12-march-2020](https://www.gov.uk/government/speeches/pm-statement-on-coronavirus-12-march-2020)).
- 388 4. GOV.UK, Prime Minister's statement on coronavirus (COVID-19): 20 March 2020 -  
389 GOV.UK, (available at [https://www.gov.uk/government/speeches/pm-statement-on-](https://www.gov.uk/government/speeches/pm-statement-on-coronavirus-20-march-2020)  
390 [coronavirus-20-march-2020](https://www.gov.uk/government/speeches/pm-statement-on-coronavirus-20-march-2020)).
- 391 5. GOV.UK, Prime Minister's statement on coronavirus (COVID-19): 22 March 2020 -  
392 GOV.UK, (available at [https://www.gov.uk/government/speeches/pm-statement-on-](https://www.gov.uk/government/speeches/pm-statement-on-coronavirus-22-march-2020)  
393 [coronavirus-22-march-2020](https://www.gov.uk/government/speeches/pm-statement-on-coronavirus-22-march-2020)).
- 394 6. B. Jeffrey, C. E. Walters, K. E. C. Ainslie, O. Eales, C. Ciavarella, S. Bhatia, S. Hayes,  
395 M. Baguelin, A. Boonyasiri, N. F. Brazeau, G. Cuomo-Dannenburg, R. G. FitzJohn, K.  
396 Gaythorpe, W. Green, N. Imai, T. A. Mellan, S. Mishra, P. Nouvellet, H. J. T. Unwin,  
397 R. Verity, M. Vollmer, C. Whittaker, N. M. Ferguson, C. A. Donnelly, S. Riley,  
398 Anonymised and aggregated crowd level mobility data from mobile phones suggests  
399 that initial compliance with covid-19 social distancing interventions was high and  
400 geographically consistent across the UK. *Wellcome Open Res.* **5**, 1–10 (2020).
- 401 7. HM Revenue & Customs, Get a discount with the Eat Out to Help Out Scheme.  
402 [www.gov.uk](http://www.gov.uk) (2020).
- 403 8. GOV.UK, Rule of six comes into effect to tackle coronavirus - GOV.UK, (available at  
404 [https://www.gov.uk/government/news/rule-of-six-comes-into-effect-to-tackle-](https://www.gov.uk/government/news/rule-of-six-comes-into-effect-to-tackle-coronavirus)  
405 [coronavirus](https://www.gov.uk/government/news/rule-of-six-comes-into-effect-to-tackle-coronavirus)).

- 406 9. GOV.UK, Prime Minister announces new local COVID Alert Levels - GOV.UK,  
407 (available at [https://www.gov.uk/government/news/prime-minister-announces-new-  
409 10. GOV.UK, Prime Minister announces new national restrictions - GOV.UK, \(available at  
410 \[https://www.gov.uk/government/news/prime-minister-announces-new-national-  
412 11. NHS Digital, SGSS and CHES data - NHS Digital, \\(available at  
413 \\[https://digital.nhs.uk/about-nhs-digital/corporate-information-and-  
416 12. NHS, Overview | COVID-19 rapid guideline: critical care in adults | Guidance | NICE.  
417 13. N. F. Brazeau, R. Verity, S. Jenks, H. Fu, C. Whittaker, P. Winskill, I. Dorigatti, P.  
418 Walker, S. Riley, R. P. Schnekenberg, H. Hoeltgebaum, T. A. Mellan, S. Mishra, H. T.  
419 Juliette Unwin, O. J. Watson, Z. M. Cucunubá, M. Baguelin, L. Whittles, S. Bhatt, A.  
420 C. Ghani, N. M. Ferguson, L. C. Okell, Infection Fatality Ratio: Estimates from  
421 Seroprevalence, doi:10.25561/83545.  
422 14. R. A. Armstrong, A. D. Kane, T. M. Cook, Outcomes from intensive care in patients  
423 with COVID-19: a systematic review and meta-analysis of observational studies.  
424 \\\*Anaesthesia\\\*. \\\*\\\*75\\\*\\\*, 1340–1349 \\\(2020\\\).  
425 15. Public Health England, Sero-surveillance of COVID-19 - GOV.UK, \\\(available at  
426 \\\[https://www.gov.uk/government/publications/national-covid-19-surveillance-  
428 16. F. J. Ibarondo, J. A. Fulcher, D. Goodman-Meza, J. Elliott, C. Hofmann, M. A.  
429 Hausner, K. G. Ferbas, N. H. Tobin, G. M. Aldrovandi, O. O. Yang, Rapid Decay of  
430 Anti–SARS-CoV-2 Antibodies in Persons with Mild Covid-19. \\\\*N. Engl. J. Med.\\\\*, 1–2  
431 \\\\(2020\\\\).  
432 17. L. H. Nguyen, D. A. Drew, M. S. Graham, A. D. Joshi, C. G. Guo, W. Ma, R. S. Mehta,\\\]\\\(https://www.gov.uk/government/publications/national-covid-19-surveillance-<br/>427 reports/sero-surveillance-of-covid-19\\\)\\]\\(https://digital.nhs.uk/about-nhs-digital/corporate-information-and-<br/>414 documents/directions-and-data-provision-notices/data-provision-notices-dpns/sgss-<br/>415 and-chess-data\\)\]\(https://www.gov.uk/government/news/prime-minister-announces-new-national-<br/>411 restrictions\)](https://www.gov.uk/government/news/prime-minister-announces-new-<br/>408 local-covid-alert-levels)

433 E. T. Warner, D. R. Sikavi, C. H. Lo, S. Kwon, M. Song, L. A. Mucci, M. J. Stampfer,  
434 W. C. Willett, A. H. Eliassen, J. E. Hart, J. E. Chavarro, J. W. Rich-Edwards, R.  
435 Davies, J. Capdevila, K. A. Lee, M. N. Lochlainn, T. Varsavsky, C. H. Sudre, M. J.  
436 Cardoso, J. Wolf, T. D. Spector, S. Ourselin, C. J. Steves, A. T. Chan, C. M. Albert, G.  
437 Andreotti, B. Bala, B. A. Balasubramanian, L. E. Beane-Freeman, J. S. Brownstein, F.  
438 J. Bruinsma, J. Coresh, R. Costa, A. N. Cowan, A. Deka, S. L. Deming-Halverson, M.  
439 Elena Martinez, M. E. Ernst, J. C. Figueiredo, P. Fortuna, P. W. Franks, L. B.  
440 Freeman, C. D. Gardner, I. M. Ghobrial, C. A. Haiman, J. E. Hall, J. H. Kang, B.  
441 Kirpach, K. C. Koenen, L. D. Kubzansky, J. V Lacey, L. Le Marchand, X. Lin, P.  
442 Lutsey, C. R. Marinac, M. E. Martinez, R. L. Milne, A. M. Murray, D. Nash, J. R.  
443 Palmer, A. V Patel, E. Pierce, M. M. Robertson, L. Rosenberg, D. P. Sandler, S. H.  
444 Schurman, K. Sewalk, S. V Sharma, C. J. Sidey-Gibbons, L. Slevin, J. W. Smoller, C.  
445 J. Steves, M. I. Tiirikainen, S. T. Weiss, L. R. Wilkens, F. Zhang, Risk of COVID-19  
446 among front-line health-care workers and the general community: a prospective  
447 cohort study. *Lancet Public Heal.* **5**, e475--e483 (2020).

448 18. GOV.UK, COVID-19: number of outbreaks in care homes - management information,  
449 (available at [https://www.gov.uk/government/statistical-data-sets/covid-19-number-of-](https://www.gov.uk/government/statistical-data-sets/covid-19-number-of-outbreaks-in-care-homes-management-information#history)  
450 [outbreaks-in-care-homes-management-information#history](https://www.gov.uk/government/statistical-data-sets/covid-19-number-of-outbreaks-in-care-homes-management-information#history)).

451 19. S. N. Ladhani, J. Y. Chow, R. Janarthanan, J. Fok, E. Crawley-Boevey, A. Vusirikala,  
452 E. Fernandez, M. S. Perez, S. Tang, K. Dun-Campbell, E. W. Evans, A. Bell, B. Patel,  
453 Z. Amin-Chowdhury, F. Aiano, K. Paranthaman, T. Ma, M. Saavedra-Campos, R.  
454 Myers, J. Ellis, A. Lackenby, R. Gopal, M. Patel, C. Brown, M. Chand, K. Brown, M. E.  
455 Ramsay, S. Hopkins, N. Shetty, M. Zambon, Investigation of SARS-CoV-2 outbreaks  
456 in six care homes in London, April 2020. *EClinicalMedicine.* **26**, 100533 (2020).

457 20. J. K. Burton, G. Bayne, C. Evans, F. Garbe, D. Gorman, N. Honhold, D. McCormick,  
458 R. Othieno, J. E. Stevenson, S. Swietlik, K. E. Templeton, M. Tranter, L. Willocks, B.  
459 Guthrie, Evolution and effects of COVID-19 outbreaks in care homes: a population

- 460 analysis in 189 care homes in one geographical region of the UK. *Lancet Heal.*  
461 *Longev.* **1**, e21–e31 (2020).
- 462 21. L. J. Strausbaugh, S. R. Sukumar, C. L. Joseph, Infectious disease outbreaks in  
463 nursing homes: An unappreciated hazard for frail elderly persons. *Clin. Infect. Dis.* **36**,  
464 870–876 (2003).
- 465 22. T. Inns, D. Wilson, P. Manley, J. P. Harris, S. J. O'Brien, R. Vivancos, What  
466 proportion of care home outbreaks are caused by norovirus? An analysis of viral  
467 causes of gastroenteritis outbreaks in care homes, North East England, 2016-2018.  
468 *BMC Infect. Dis.* **20**, 2 (2019).
- 469 23. P. N. Perez-Guzman, A. Daunt, S. Mukherjee, P. Crook, R. Forlano, M. D. Kont, A.  
470 Løchen, M. Vollmer, P. Middleton, R. Judge, C. Harlow, A. Soubieres, G. Cooke, P. J.  
471 White, T. B. Hallett, P. Aylin, N. Ferguson, K. Hauck, M. R. Thursz, S. Nayagam,  
472 Clinical characteristics and predictors of outcomes of hospitalized patients with  
473 COVID-19 in a multi-ethnic London NHS Trust: a retrospective cohort study. *Clin.*  
474 *Infect. Dis.*, 1–11 (2020).
- 475 24. A. B. Docherty, E. M. Harrison, C. A. Green, H. E. Hardwick, R. Pius, L. Norman, K.  
476 A. Holden, J. M. Read, F. Dondelinger, G. Carson, L. Merson, J. Lee, D. Plotkin, L.  
477 Sigfrid, S. Halpin, C. Jackson, C. Gamble, P. W. Horby, J. S. Nguyen-Van-Tam, A.  
478 Ho, C. D. Russell, J. Dunning, P. J. M. Openshaw, J. K. Baillie, M. G. Semple,  
479 Features of 20 133 UK patients in hospital with covid-19 using the ISARIC WHO  
480 Clinical Characterisation Protocol: Prospective observational cohort study. *BMJ.* **369**,  
481 1–12 (2020).
- 482 25. S. Tabata, K. Imai, S. Kawano, M. Ikeda, T. Kodama, K. Miyoshi, H. Obinata, S.  
483 Mimura, T. Kodera, M. Kitagaki, M. Sato, S. Suzuki, T. Ito, Y. Uwabe, K. Tamura,  
484 Clinical characteristics of COVID-19 in 104 people with SARS-CoV-2 infection on the  
485 Diamond Princess cruise ship: a retrospective analysis. *Lancet Infect. Dis.* **20**, 1043–  
486 1050 (2020).

- 487 26. P. Vetter, D. L. Vu, A. G. L’Huillier, M. Schibler, L. Kaiser, F. Jacqueroiz, Clinical  
488 features of covid-19. *BMJ*. **369**, 1–2 (2020).
- 489 27. R. Verity, L. C. Okell, I. Dorigatti, P. Winskill, C. Whittaker, N. Imai, G. Cuomo-  
490 Dannenburg, H. Thompson, P. G. T. Walker, H. Fu, A. Dighe, J. T. Griffin, M.  
491 Baguelin, S. Bhatia, A. Boonyasiri, A. Cori, Z. Cucunubá, R. FitzJohn, K. Gaythorpe,  
492 W. Green, A. Hamlet, W. Hinsley, D. Laydon, G. Nedjati-Gilani, S. Riley, S. van  
493 Elsland, E. Volz, H. Wang, Y. Wang, X. Xi, C. A. Donnelly, A. C. Ghani, N. M.  
494 Ferguson, Estimates of the severity of coronavirus disease 2019: a model-based  
495 analysis. *Lancet Infect. Dis.* (2020), doi:10.1016/S1473-3099(20)30243-7.
- 496 28. The RECOVERY Collaborative Group, Dexamethasone in Hospitalized Patients with  
497 Covid-19 — Preliminary Report. *N. Engl. J. Med.*, 1–11 (2020).
- 498 29. L. I. Horwitz, S. A. Jones, R. J. Cerfolio, F. Francois, J. Greco, B. Rudy, C. M. Petrilli,  
499 Trends in COVID-19 Risk-Adjusted Mortality Rates. *J. Hosp. Med.* **23**, 2020 (2020).
- 500 30. A. W. D. Edridge, J. Kaczorowska, A. C. R. Hoste, M. Bakker, M. Klein, K. Loens, M.  
501 F. Jebbink, A. Matser, C. M. Kinsella, P. Rueda, M. Ieven, H. Goossens, M. Prins, P.  
502 Sastre, M. Deijis, L. van der Hoek, Seasonal coronavirus protective immunity is short-  
503 lasting. *Nat. Med.* (2020), doi:10.1038/s41591-020-1083-1.
- 504 31. S. M. Kissler, C. Tedijanto, E. Goldstein, Y. H. Grad, M. Lipsitch, Projecting the  
505 transmission dynamics of SARS-CoV-2 through the postpandemic period. *Science*  
506 (80- ). **368**, 860–868 (2020).
- 507 32. L. C. Okell, R. Verity, O. J. Watson, S. Mishra, P. Walker, C. Whittaker, A.  
508 Katzourakis, C. A. Donnelly, S. Riley, A. C. Ghani, A. Gandy, S. Flaxman, N. M.  
509 Ferguson, S. Bhatt, Correspondence Have deaths from COVID-19 in Europe  
510 plateaued due to herd. *Lancet*. **395**, e110–e111 (2020).
- 511 33. Academy of Medical Science, Preparing for a challenging winter 2020/21, 79 (2020).
- 512 34. NHS England and NHS Improvement, “Hospital Onset Covid-19: IPC evidence from  
513 recent survey and next steps.”

- 514 35. G. Iacobucci, Covid-19: Doctors sound alarm over hospital transmissions. *BMJ*. **369**,  
515 m2013 (2020).
- 516 36. D. Buitrago-Garcia, D. Egli-Gany, M. J. Counotte, S. Hossmann, H. Imeri, A. M.  
517 Ipekci, G. Salanti, N. Low, Occurrence and transmission potential of asymptomatic  
518 and presymptomatic SARS-CoV-2 infections: A living systematic review and meta-  
519 analysis. *PLoS Med.* **17**, e1003346 (2020).
- 520 37. S. Riley, C. E. Walters, H. Wang, O. Eales, K. E. C. Ainslie, C. Atchison, C. Fronterre,  
521 P. J. Diggle, D. Ashby, C. A. Donnelly, G. Cooke, W. Barclay, H. Ward, A. Darzi, P.  
522 Elliott, *medRxiv*, in press, doi:10.1101/2020.12.15.20248244.
- 523 38. Office for National Statistics, Office for National Statistics, (available at  
524 <https://www.ons.gov.uk/>).
- 525 39. Care Quality Commission, [ARCHIVED CONTENT] UK Government Web Archive -  
526 The National Archives, (available at  
527 [https://webarchive.nationalarchives.gov.uk/20200605160439/https://www.cqc.org.uk/fi](https://webarchive.nationalarchives.gov.uk/20200605160439/https://www.cqc.org.uk/files/cqc-care-directory-filters-1-june-2020)  
528 [les/cqc-care-directory-filters-1-june-2020](https://webarchive.nationalarchives.gov.uk/20200605160439/https://www.cqc.org.uk/files/cqc-care-directory-filters-1-june-2020)).
- 529 40. GOV.UK, "Care Homes Analysis Background" (2020).
- 530 41. Age UK, Later Life in the United Kingdom 2019, (available at  
531 [https://www.ageuk.org.uk/globalassets/age-uk/documents/reports-and-](https://www.ageuk.org.uk/globalassets/age-uk/documents/reports-and-publications/late_r_life_uk_factsheet.pdf)  
532 [publications/late\\_r\\_life\\_uk\\_factsheet.pdf](https://www.ageuk.org.uk/globalassets/age-uk/documents/reports-and-publications/late_r_life_uk_factsheet.pdf)).
- 533 42. J. Mossong, N. Hens, M. Jit, P. Beutels, K. Auranen, R. Mikolajczyk, M. Massari, S.  
534 Salmaso, G. S. Tomba, J. Wallinga, J. Heijne, M. Sadkowska-Todys, M. Rosinska, W.  
535 J. Edmunds, Social contacts and mixing patterns relevant to the spread of infectious  
536 diseases. *PLoS Med.* **5**, 381–391 (2008).
- 537 43. S. A. Lauer, K. H. Grantz, Q. Bi, F. K. Jones, Q. Zheng, H. R. Meredith, A. S. Azman,  
538 N. G. Reich, J. Lessler, The incubation period of coronavirus disease 2019 (CoVID-  
539 19) from publicly reported confirmed cases: Estimation and application. *Ann. Intern.*  
540 *Med.* **172**, 577–582 (2020).



- 541 44. Q. Bi, Y. Wu, S. Mei, C. Ye, X. Zou, Z. Zhang, X. Liu, L. Wei, S. A. Truelove, T.  
542 Zhang, W. Gao, C. Cheng, X. Tang, X. Wu, Y. Wu, B. Sun, S. Huang, Y. Sun, J.  
543 Zhang, T. Ma, J. Lessler, T. Feng, Epidemiology and transmission of COVID-19 in  
544 391 cases and 1286 of their close contacts in Shenzhen, China: a retrospective  
545 cohort study. *Lancet Infect Dis* (2020), doi:10.1016/s1473-3099(20)30287-5.
- 546 45. M. Bernabeu-Wittel, J. E. Ternero-Vega, P. Díaz-Jiménez, C. Conde-Guzmán, M. D.  
547 Nieto-Martín, L. Moreno-Gaviño, J. Delgado-Cuesta, M. Rincón-Gómez, L. Giménez-  
548 Miranda, . D Navarro-Amuedo, M. M. Muñoz-García, S. Calzón-Fernández, M. Ollero-  
549 Baturone, Death risk stratification in elderly patients with covid-19. A comparative  
550 cohort study in nursing homes outbreaks. *Arch. Gerontol. Geriatr.* **91**, 104240 (2020).
- 551 46. S. Omar, C. Bartz, S. Becker, S. Basenach, S. Pfeifer, C. Trapp, H. Hamm, H. C.  
552 Schlichting, M. Friederichs, U. Koch, C. Jestrabek, E. Hilger, M. Vogt, K. Jahn, S.  
553 Chen, T. Barnighausen, P. Zanger, Duration of SARS-CoV-2 RNA detection in  
554 COVID-19 patients in home isolation, Rhineland-Palatinate, Germany, 2020 - an  
555 interval-censored survival analysis. *Eurosurveillance.* **25**, 1–8 (2020).
- 556 47. B. Benny, G. Amandine, P. Kc, H. Sarah, M. Abby, C. Caitlin, S. Van, L.-S. James, O.  
557 Affiliations, Quantifying antibody kinetics and RNA shedding during early-phase  
558 SARS-CoV-2 infection, doi:10.1101/2020.05.15.20103275.
- 559 48. S. Funk, Socialmixr: Social Mixing Matrices for Infectious Disease Modelling (2018).
- 560 49. GOV.UK, Prime Minister's statement on coronavirus (COVID-19): 25 March 2020 -  
561 GOV.UK, (available at [https://www.gov.uk/government/speeches/pm-statement-on-](https://www.gov.uk/government/speeches/pm-statement-on-coronavirus-25-march-2020)  
562 [coronavirus-25-march-2020](https://www.gov.uk/government/speeches/pm-statement-on-coronavirus-25-march-2020)).
- 563 50. GOV.UK, Prime Minister's statement on coronavirus (COVID-19): 11 May 2020 -  
564 GOV.UK, (available at [https://www.gov.uk/government/speeches/pm-statement-on-](https://www.gov.uk/government/speeches/pm-statement-on-coronavirus-11-may-2020)  
565 [coronavirus-11-may-2020](https://www.gov.uk/government/speeches/pm-statement-on-coronavirus-11-may-2020)).
- 566 51. GOV.UK, Prime Minister sets out timeline for retail to reopen in June - GOV.UK,  
567 (available at <https://www.gov.uk/government/news/prime-minister-sets-out-timeline->

- 568 for-retail-to-reopen-in-june).
- 569 52. GOV.UK, Pubs, restaurants and hairdressers to reopen from 4 July - GOV.UK,  
570 (available at [https://www.gov.uk/government/news/pubs-restaurants-and-](https://www.gov.uk/government/news/pubs-restaurants-and-hairdressers-to-reopen-from-4-july)  
571 [hairdressers-to-reopen-from-4-july](https://www.gov.uk/government/news/pubs-restaurants-and-hairdressers-to-reopen-from-4-july)).
- 572 53. GOV.UK, Eat Out to Help Out launches today – with government paying half on  
573 restaurant bills - GOV.UK, (available at [https://www.gov.uk/government/news/eat-out-](https://www.gov.uk/government/news/eat-out-to-help-out-launches-today-with-government-paying-half-on-restaurant-bills)  
574 [to-help-out-launches-today-with-government-paying-half-on-restaurant-bills](https://www.gov.uk/government/news/eat-out-to-help-out-launches-today-with-government-paying-half-on-restaurant-bills)).
- 575 54. GOV.UK, Schools and colleges to reopen in full in September - GOV.UK, (available at  
576 [https://www.gov.uk/government/news/schools-and-colleges-to-reopen-in-full-in-](https://www.gov.uk/government/news/schools-and-colleges-to-reopen-in-full-in-september)  
577 [september](https://www.gov.uk/government/news/schools-and-colleges-to-reopen-in-full-in-september)).
- 578 55. O. Diekmann, J. A. P. Heesterbeek, J. A. J. Metz, On the definition and the  
579 computation of the basic reproduction ratio  $R_0$  in models for infectious diseases in  
580 heterogeneous populations. *J. Math. Biol.* **28**, 365–382 (1990).
- 581 56. D. T. Gillespie, Approximate accelerated stochastic simulation of chemically reacting  
582 systems. *J. Chem. Phys.* **115**, 1716–1733 (2001).
- 583 57. Department of Health and Social Care, COVID-19 testing data: methodology note.  
584 [www.gov.uk](http://www.gov.uk) (2020).
- 585 58. I. M. C. Martin, C. A. Ison, D. M. Aanensen, K. A. Fenton, B. G. Spratt, Rapid  
586 Sequence-Based Identification of Gonococcal Transmission Clusters in a Large  
587 Metropolitan Area. *J. Infect. Dis.* **189**, 1497–1505 (2004).
- 588 59. P. Del Moral, A. Doucet, A. Jasra, Sequential Monte Carlo samplers. *J. R. Stat. Soc.*  
589 *Ser. B Stat. Methodol.* **68**, 411–436 (2006).
- 590 60. C. Andrieu, A. Doucet, R. Holenstein, Particle Markov chain Monte Carlo methods. *J.*  
591 *R. Stat. Soc. Ser. B Stat. Methodol.* **72**, 269–342 (2010).
- 592 61. N. J. Gordon, D. J. Salmond, A. F. M. Smith, Novel approach to nonlinear/non-  
593 gaussian Bayesian state estimation. *IEE Proceedings, Part F Radar Signal Process.*  
594 **140**, 107–113 (1993).

- 595 62. M. Baguelin, E. Knock, L. K. Whittles, R. FitzJohn, J. Lees, sircovid (2020).
- 596 63. E. S. Knock, L. K. Whittles, P. N. Perez-Guzman, S. Bhatia, F. Guntoro, O. J. Watson,  
597 C. Whittaker, N. M. Ferguson, A. Cori, M. Baguelin, R. G. FitzJohn, J. A. Lees,  
598 Reproducible parallel inference and simulation of stochastic state space models using  
599 odin, dust, and mcstate. *Wellcome Open Res.* **5**, 288 (2020).
- 600 64. M. Plummer, N. Best, K. Cowles, K. Vines, CODA: Convergence Diagnosis and  
601 Output Analysis for MCMC. *R News.* **6**, 7–11 (2006).
- 602 65. A. Gelman, D. B. Rubin, Inference from iterative simulation using multiple sequences.  
603 *Stat. Sci.* **7**, 457–472 (1992).
- 604 66. R. Verity, R. FitzJohn, mrc-ide/markovid at version1.5, (available at  
605 <https://github.com/mrc-ide/markovid/tree/version1.5>).
- 606 67. C. I. Jarvis, K. Van Zandvoort, A. Gimma, K. Prem, M. Auzenbergs, K. O'Reilly, G.  
607 Medley, J. C. Emery, R. M. G. J. Houben, N. Davies, E. S. Nightingale, S. Flasche, T.  
608 Jombart, J. Hellewell, S. Abbott, J. D. Munday, N. I. Bosse, S. Funk, F. Sun, A. Endo,  
609 A. Rosello, S. R. Procter, A. J. Kucharski, T. W. Russell, G. Knight, H. Gibbs, Q.  
610 Leclerc, B. J. Quilty, C. Diamond, Y. Liu, M. Jit, S. Clifford, C. A. B. Pearson, R. M.  
611 Eggo, A. K. Deol, P. Klepac, G. J. Rubin, W. J. Edmunds, Quantifying the impact of  
612 physical distance measures on the transmission of COVID-19 in the UK. *BMC Med.*  
613 **18**, 1–10 (2020).
- 614 68. E. Lavezzo, E. Franchin, C. Ciavarella, G. Cuomo-Dannenburg, L. Barzon, C. Del  
615 Vecchio, L. Rossi, R. Manganelli, A. Loregian, N. Navarin, D. Abate, M. Sciro, S.  
616 Merigliano, E. De Canale, M. C. Vanuzzo, V. Besutti, F. Saluzzo, F. Onelia, M.  
617 Pacenti, S. G. Parisi, G. Carretta, D. Donato, L. Flor, S. Cocchio, G. Masi, A. Sperduti,  
618 L. Cattarino, R. Salvador, M. Nicoletti, F. Caldart, G. Castelli, E. Nieddu, B. Labella, L.  
619 Fava, M. Drigo, K. A. M. Gaythorpe, K. E. C. Ainslie, M. Baguelin, S. Bhatt, A.  
620 Boonyasiri, O. Boyd, L. Cattarino, C. Ciavarella, H. L. Coupland, Z. Cucunubá, G.  
621 Cuomo-Dannenburg, B. A. Djafaara, C. A. Donnelly, I. Dorigatti, S. L. van Elsland, R.

622 FitzJohn, S. Flaxman, K. A. M. Gaythorpe, W. D. Green, T. Hallett, A. Hamlet, D.  
623 Haw, N. Imai, B. Jeffrey, E. Knock, D. J. Laydon, T. Mellan, S. Mishra, G. Nedjati-  
624 Gilani, P. Nouvellet, L. C. Okell, K. V. Parag, S. Riley, H. A. Thompson, H. J. T.  
625 Unwin, R. Verity, M. A. C. Vollmer, P. G. T. Walker, C. E. Walters, H. Wang, Y. Wang,  
626 O. J. Watson, C. Whittaker, L. K. Whittles, X. Xi, N. M. Ferguson, A. R. Brazzale, S.  
627 Toppo, M. Trevisan, V. Baldo, C. A. Donnelly, N. M. Ferguson, I. Dorigatti, A. Crisanti,  
628 Suppression of a SARS-CoV-2 outbreak in the Italian municipality of Vo'. *Nature*  
629 (2020), doi:10.1038/s41586-020-2488-1.

630 69. NHS England and NHS Improvement, Statistics » COVID-19 Hospital Activity,  
631 (available at [https://www.england.nhs.uk/statistics/statistical-work-areas/covid-19-](https://www.england.nhs.uk/statistics/statistical-work-areas/covid-19-hospital-activity/)  
632 [hospital-activity/](https://www.england.nhs.uk/statistics/statistical-work-areas/covid-19-hospital-activity/)).

633  
634

### 635 **Acknowledgements**

636 We thank all the colleagues at Public Health England (PHE) and frontline health  
637 professionals who have driven and continue to drive the daily response to the epidemic, but  
638 also for providing the necessary data to inform this study. This work would not have been  
639 possible without their dedication and expertise. The use of pillar 2 PCR testing data was  
640 made possible thanks to PHE colleagues and we extend our thanks to Dr Nick Gent and Dr  
641 André Charlett for facilitation and their insights into these data. The use of serological data  
642 was made possible by colleagues at PHE Porton Down, Colindale, and the NHS Blood  
643 Transfusion Service. We are particularly grateful to Dr Gayatri Amirthalingam and Prof Nick  
644 Andrews for helpful discussions around these data. We also thank the entire Imperial  
645 College London Covid-19 Response Team for their support and feedback throughout. This  
646 work was supported by the NIHR HPRU in Modelling and Health Economics, a partnership  
647 between PHE, Imperial College London and LSHTM (grant code NIHR200908). We  
648 acknowledge funding from the MRC Centre for Global Infectious Disease Analysis

649 (reference MR/R015600/1), jointly funded by the UK Medical Research Council (MRC) and  
650 the UK Foreign, Commonwealth & Development Office (FCDO), under the MRC/FCDO  
651 Concordat agreement and is also part of the EDCTP2 programme supported by the  
652 European Union.

653

#### 654 **Disclaimer**

655 The views expressed are those of the authors and not necessarily those of the United  
656 Kingdom (UK) Department of Health and Social Care, the National Health Service, the  
657 National Institute for Health Research (NIHR), Public Health England (PHE), UK MRC, UKRI  
658 or European Union.

659

#### 660 **List of Supplementary Materials**

661 Supplementary materials (Materials and Methods, Supplementary Results)  
662 Supplementary data files: data\_rtm.csv, data\_serology.csv, support\_progression.csv,  
663 support\_severity.csv

664

#### 665 **Data availability statement**

666 All code and de-identified regionally aggregated data (see supplementary materials for full  
667 details) required to reproduce this analysis are available at [https://github.com/mrc-](https://github.com/mrc-ide/sarscov2-transmission-england)  
668 [ide/sarscov2-transmission-england](https://github.com/mrc-ide/sarscov2-transmission-england) (<https://zenodo.org/record/4384864>)

# Supplementary Materials

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42

## Table of Contents

<b>1</b>	<b>Materials and Methods</b>	<b>2</b>
<b>1.1</b>	<b>Data sources</b>	<b>2</b>
1.1.1	Hospital admissions and bed occupancy	2
1.1.2	Deaths	2
1.1.3	Pillar 2 testing	3
1.1.4	Serology surveys	3
1.1.5	REACT-1 prevalence survey	3
1.1.6	Summary of the data used for calibration	3
1.1.7	Other data sources	4
<b>1.2</b>	<b>Evidence synthesis</b>	<b>4</b>
<b>1.3</b>	<b>Model description</b>	<b>6</b>
1.3.1	Stratification of population into groups	6
1.3.2	Progression of infection and hospitalisation	6
1.3.3	Progression of infection and hospitalisation	8
1.3.4	Age-varying and time-varying infection progression probabilities	11
<b>1.4</b>	<b>Reproduction number <math>R_t</math> and effective reproduction number <math>R_{teff}</math></b>	<b>12</b>
<b>1.5</b>	<b>Infection severity</b>	<b>12</b>
<b>1.6</b>	<b>Compartmental model equations</b>	<b>13</b>
<b>1.7</b>	<b>Observation process</b>	<b>18</b>
1.7.1	Notation for distributions used in this section	19
1.7.2	Hospital admissions and new diagnoses in hospital	19
1.7.3	Hospital bed occupancy by confirmed COVID-19 cases	19
1.7.4	Hospital and care homes COVID-19 deaths	20
1.7.5	Serosurveys	20
1.7.6	PCR testing	21
<b>1.8</b>	<b>Bayesian inference and model fitting</b>	<b>22</b>
<b>1.9</b>	<b>Prior distributions and parameter calibration</b>	<b>24</b>
1.9.1	Risk of hospital admission	24
1.9.2	Severity and hospital progression	25
1.9.3	Serosurveys	29
1.9.4	PCR positivity	29
1.9.5	Local start date of the epidemic	29
1.9.6	Time-varying transmission rates	30
1.9.7	Transmission within care homes	30
1.9.8	Parameters relating to Pillar 2 testing	30
<b>2</b>	<b>Supplementary Results</b>	<b>35</b>
<b>2.1</b>	<b>Model fitting and validation</b>	<b>35</b>
<b>2.2</b>	<b>Severity estimates</b>	<b>36</b>
<b>2.3</b>	<b>Supplementary counterfactual analysis</b>	<b>37</b>

44

45

46 **1 Materials and Methods**

47 Understanding the transmission of SARS-CoV-2 is challenging. The available data are  
 48 subject to competing biases, such as dependence on case definition for testing and  
 49 reporting, as well as being influenced by capacity and logistical constraints. These factors  
 50 are further complicated by the nature of SARS-CoV-2 transmission, whereby a substantial  
 51 proportion of infected individuals develop very mild symptoms, or remain asymptomatic, but  
 52 are nonetheless able to infect others (1). In this section, we describe the data used in our  
 53 analyses, give details on the dynamic transmission model, and present the methods used for  
 54 fitting the model to the various data sources, accounting for the inherent biases in those  
 55 data.

56

57 **1.1 Data sources**

58 Here we detail the datasets used to calibrate the model to the regional epidemics. We fitted  
 59 our model to time series data spanning 16th March 2020 to 2nd December 2020 (inclusive),  
 60 using the data available to us on 14th December 2020, by which point the effect of  
 61 remaining reporting lags would be minimal.

62

63 *1.1.1 Hospital admissions and bed occupancy*

64 We use healthcare data for each NHS region from the UK Government Dashboard  
 65 (supplementary data files: *data\_rtm.csv*, columns: *phe\_admissions*, *phe\_occupied*,  
 66 *phe\_patients*) (2).

67 For admissions data, we use the daily number of confirmed COVID-19 patients admitted to  
 68 hospital, which includes people admitted to hospital who tested positive for COVID-19 in the  
 69 14 days prior to admission and inpatients who tested positive in hospital after admission,  
 70 with the latter being reported as admitted on the day prior to their diagnosis.

71 For ICU bed occupancy, we use the daily number of (confirmed) COVID-19 patients in beds  
 72 which are capable of delivering mechanical ventilation.

73 For the occupancy in general (i.e. non-ICU) hospital beds, we use the daily number of  
 74 confirmed COVID-19 patients in hospital beds with ICU occupancy subtracted.

75 *1.1.2 Deaths*

76 We use the number of deaths by date of death for people who had a positive COVID-19 test  
 77 result and died within 28 days of their first positive test provided Public Health England.  
 78 These can be found on (2). We also use the number among these deaths occurring in  
 79 hospital (as reported by NHS England) and consider the remainder to have occurred in care  
 80 homes. While non-hospital deaths may include deaths in other settings, such as in private  
 81 residences, comparison with ONS data suggests that care home deaths from COVID-19  
 82 may also have been under-reported. As such we consider non-hospital deaths to be an  
 83 appropriate proxy for care home deaths, and do not expect the margin for under or over-  
 84 ascertainment to affect our conclusions. These data were provided by PHE and the data we  
 85 have been using is provided as a supplementary file (supplementary data file: *data\_rtm.csv*,  
 86 columns: *death2*, *death3*) to allow reproducibility of our analysis.

87           1.1.3 *Pillar 2 testing*

88 We use pillar 2 testing data (see supplementary data files), which covers PCR testing for the  
89 general population (as compared with pillar 1 testing, which mainly occurred in hospitals).  
90 Since such testing was not available to the whole population for much of the spring wave of  
91 the pandemic, we only use this data from June 1<sup>st</sup> onwards.

92 We use the daily number of positives and negative tests by specimen date. Each individual  
93 who tested positive was only counted once in the number of positives, on the specimen date  
94 of their first positive test. Multiple negatives were allowed per individual, but the negatives of  
95 all individuals who ever tested positive had been removed. We only consider PCR tests and  
96 thus exclude lateral flow tests, which have been introduced recently in trials of population  
97 mass testing. We also only use pillar 2 data for those aged 25 or over, to avoid bias resulting  
98 from increased testing of university students around the reopening of universities  
99 (supplementary data file: *data\_rtm.csv*, columns: *pillar2\_negatives\_non\_lft\_over25*,  
100 *pillar2\_positives\_over25*).

101           1.1.4 *Serology surveys*

102 Serological survey data come from antibody testing by Public Health England of samples  
103 from healthy adult blood donors, supplied by NHS Blood and Transplant (NHSBT)  
104 (supplementary data file: *data\_serology.csv*).

105           1.1.5 *REACT-1 prevalence survey*

106 We use the daily number of positives and negatives by specimen date from the first 7 rounds  
107 of the REACT-1 (Real-time Assessment of Community Transmission) infection prevalence  
108 survey (supplementary data file: *data\_rtm.csv*, columns: *react\_positive*, *react\_samples*) (3).  
109 Note that results published in REACT preprints use data aggregated using the administrative  
110 regions of England, whereas for the purposes of this study the data has been aggregated  
111 using NHS regions. Additionally, small changes can occur in the aggregated datasets that  
112 were published in real time because of participant withdrawals and additional data cleaning.

113           1.1.6 *Summary of the data used for calibration*

114 Table S 1 details the datasets used to calibrate the model to the regional epidemics.

115 *Table S 1: Data sources and definitions.*

<b>Data type</b>	<b>Description</b>	<b>Source</b>	<b>Reference</b>
<b>Hospital deaths</b>	Daily number of COVID-19 deaths reported by NHS England within 28 days of a positive result	PHE	See data supplement. These data underlie what is released on (2)
<b>Care home deaths</b>	Daily number of COVID-19 deaths not reported by NHS England within 28 days of a positive result	PHE	See data supplement. These data underlie what is released on (2)
<b>ICU occupancy</b>	Daily number of confirmed COVID-19 patients in ICU	Gov.uk Dashboard	(2)
<b>General bed occupancy</b>	Daily number of confirmed COVID-19 patients in non-ICU beds	Gov.uk Dashboard	(2)
<b>Admissions</b>	Daily number of confirmed COVID-19 patients admitted to hospital	Gov.uk Dashboard	(2)
<b>Pillar 2 testing</b>	Daily number of positive and negative PCR test results	PHE	See data supplement. These data underlie what is released on (2)
<b>REACT-1 testing</b>	Daily number of positive and negative PCR test results	REACT	(3)



<b>Serology</b>	Serology survey conducted on blood donors aged 15-65	PHE	See data supplement, these data are collected as part of (4)
<b>Patient progression in hospital</b>	Number of hospital admissions going down each treatment route (e.g. ICU, stepdown care) and length of stay in each ward.	CHESS	(5)

116 **1.1.7 Other data sources**

117 **1.1.7.1 Patient progression in hospital**

118 The COVID-19 Hospitalisation in England Surveillance System (CHESS) data consists of a  
 119 line list of daily individual patient-level data on COVID-19 infection in persons requiring  
 120 hospitalisation, including demographic and clinical information on severity and outcomes.  
 121 We use the individual dates of progression through hospital wards, from admission to  
 122 eventual death or discharge, to produce age-stratified estimates of hospital progression  
 123 parameters to be passed to the wider transmission model (see Section 1.9.2 and  
 124 (supplementary data file: *support\_progression.csv*, *support\_severity.csv*).

125 **1.1.7.2 Demographic data**


126 We use data from the Office for National Statistics (ONS (6)) to get the number of individuals  
 127 in each of the 17 age-groups, i.e. 16 five-year age bands (0-4, 5-9, ..., 75-79) and an 80+  
 128 group. We get the number of care-home beds in England from (7) giving us the number of  
 129 care-home beds for each NHS regions. We then got an estimate of the total population of  
 130 care-home residents in the UK from (8) that we scaled down to the England population size,  
 131 combined with the estimate of the total number of beds in England, we derived a value of the  
 132 total occupancy of care-homes of 74.2%. We assumed that the occupancy is the same in all  
 133 the NHS regions. Care-home residents are subtracted from the 4 oldest age group (5% from  
 134 age 65-69, 5% age 70-74, 15% age 75-79 and 75% age 80+ (9)). We then assume a 1:1  
 135 ratio of care-home residents to care-home workers and assume that the care-home workers  
 136 population is homogeneously distributed among the 25-65 population in the region.

137 The contact matrix between the 17 age-groups is based on the POLYMOD contact survey.  
 138 See parameterisation for more details (10).

139

140 **1.2 Evidence synthesis**

141 Figure S 1 shows the functional relationships between data sources, modelled outputs and  
 142 parameters in our study.



143

144 Figure S 1: Graph showing the functional relationships between data sources (rectangles), modelled outputs (ovals) and parameters (hexagons).

## 145 1.3 Model description

146 We developed a stochastic compartmental transmission-dynamic model incorporating  
147 hospital care pathways to reconstruct the course of the COVID-19 epidemic in the seven  
148 NHS regions of England (Figure S 2). All analyses were done by regions, and then  
149 aggregated somehow if needed (e.g. for national IFR, or cumulative incidence). In the  
150 following description we do not mention any index denoting the region and thus all notations  
151 refer to the same NHS region.

### 152 1.3.1 Stratification of population into groups

153 We divided each regional population into 19 strata, denoted by the superscript  $i$ , 17 strata  
154 representing age groups within the general population, and two separate risk groups  
155 comprising care home workers (CHW) and care home residents (CHR). The 17 age groups  
156 consisted of 16 five-year age bands (0-4, 5-9, ..., 75-79) and an 80+ group. The total size of  
157 the care home worker and resident groups were calculated assuming that 74.2% of available  
158 care home beds are occupied and there is a 1:1 carer to resident ratio (11). The care home  
159 workers were then split equally between all 8 age categories in the range 25 – 64-year-old  
160 and removed from the corresponding age categories in the general population. Despite the  
161 care-home workers being removed from all age categories in the range 25 – 64-year-old,  
162 they care-home workers are assumed to constitute one single group in our model for  
163 simplicity. The care home residents were drawn from the 65+ year old general population,  
164 such that 5% were aged 65-69, 5% aged 70-74, 15% aged 75-79 and 75% aged 80+ (9) and  
165 similarly removed from the corresponding age groups in the general population. Again,  
166 similarly to care-home workers they do constitute a single group in our model. We thus  
167 do not capture specific transmission dynamics within each care home, but rather an average  
168 mixing between residents and workers in the regional care home sector as a whole.  
169

### 170 1.3.2 Progression of infection and hospitalisation


171 Prior to the importation of COVID-19, all individuals were assumed equally susceptible to  
172 infection ( $S$ ). Upon infection, individuals pass through a latent period ( $E$ ) before becoming  
173 infectious. A proportion ( $p_C$ ) of infectious individuals develop symptoms ( $I_C$ ) while the rest  
174 remain asymptomatic ( $I_A$ ). All asymptomatic individuals are assumed to recover naturally.  
175 Those with symptoms may also recover naturally ( $R$ ), however a proportion ( $p_H^i$ , age/care  
176 home-dependant as indicated by the  $i$  superscript) develop severe disease requiring  
177 hospitalisation. Of these, a proportion ( $p_{GD}^i$ ) die at home without receiving hospital care. In  
178 practice this proportion is set to zero except among care home residents. Of the patients  
179 who are admitted to hospital, a proportion ( $p^*(t)$ ) have their COVID-19 diagnoses confirmed  
180 prior to admission, while the remainder may be diagnosed during their inpatient stay. All  
181 hospital compartments are divided between suspected (but not yet confirmed) and  
182 confirmed diagnoses (indicated by superscript  $*$ ). A proportion ( $p_{ICU}^i(t)$ ) of new hospital  
183 admissions are triaged ( $ICU_{pre}$ ) before admission to the intensive care unit ( $ICU$ ), where a  
184 fraction ( $p_{ICU_D}^i(t)$ ) die; those who do not die get out of ICU to a ward ( $W$ ) where a proportion  
185 ( $p_{W_D}^i(t)$ ) die, while the remainder recover, following an inpatient care stepdown period.  
186 Inpatients not triaged to the ICU are assigned to general hospital beds ( $H$ ), where a  
187 proportion ( $p_{H_D}^i(t)$ ) die, while the remainder recover. Recovered individuals are assumed to  
188 be immune to reinfection for at least the duration of the simulation.

189 In addition, there are two parallel flows which we use for fitting to testing data: (i) for PCR  
190 positivity and (ii) for seropositivity. Upon infection, an individual enters the PCR flow in a pre-  
191 positivity compartment ( $T_{PCR_{pre}}$ ) before moving into the PCR positivity compartment ( $T_{PCR_{pos}}$ )

192 and then ultimately into the PCR negativity compartment ( $T_{PCRneg}^i$ ). Meanwhile, individuals  
 193 move into the seropositivity flow upon becoming infectious, entering first into a pre-  
 194 seropositivity compartment ( $T_{seropre}^i$ ). A proportion of individuals ( $p_{seropos}$ ) then seroconvert  
 195 and move into the seropositivity compartment ( $T_{seropos}^i$ ), while the remainder move into the  
 196 seronegativity compartment ( $T_{seroneg}^i$ ).

197 We calibrated the duration distributions for each hospital compartment, and the age-stratified  
 198 probabilities of moving between compartments, using the analysis of individual-level patient  
 199 data (presented below in Section 1.9.2). The required Erlang distributional form was  
 200 achieved within the constraints of the modelling framework by splitting each model  
 201 compartment into  $k$  sequential sub-compartments (Table S 2).

202



203  
 204 *Figure S 2: Model structure flow diagram with rates of transition between infection states. Variable*  
 205 *names defined in text.*

206

207 *Table S 2: Description of model compartments and distribution of time spent in each. For each named*  
 208 *compartment, we give the associated duration. Due to the Markovian structure these are model*  
 209 *Erlang-like distributions with  $k_j$  the number of exponential-like compartments and  $\gamma_j$  the rate of the*  
 210 *exponential-like compartment.  $\mathbb{E}[\tau_j]$  gives the mean duration in days spent in the corresponding*  
 211 *compartment. The structure and duration of each stage was assumed to be the same for unconfirmed*  
 212 *and confirmed cases in hospital (see Figure S2). For length of stays related to hospital pathways,*  
 213 *more detail is given in section 1.9.2.*

Compartment	Description	Duration			Source
		$\tau_j \sim \text{Erlang}(k_j, \gamma_j)$		(days)	
$j$		$k_j$	$\gamma_j$	$\mathbb{E}[\tau_j] = k_j/\gamma_j$ (95% CI)	
$S$	Susceptible to infection	<i>Determined by transmission dynamics</i>			
$E$	Latent infection	2	0.44	4.6 (0.6, 12.8)	<i>Lauer et al.(12)</i>
$I_A$	Asymptomatic infection	1	0.48	2.1 (0.1, 7.7)	<i>Bi et al.(13)</i>
$I_C$	Symptomatic infection	1	0.25	4.0 (0.1, 14.8)	<i>Docherty et al.(14)</i>
$G_D$	Severe illness leading to death in the general population	2	0.40	5.0	<i>Bernabeu-Wittel et al. (15)</i>
$H_R$	Hospitalised on general ward leading to recovery	1	0.09	10.7 (0.3, 39.4)	<i>Fitted to CHESS</i>
$H_D$	Hospitalised on general ward leading to death	2	0.19	10.3 (1.3, 28.8)	<i>Fitted to CHESS</i>
$ICU_{pre}$	Triage to ICU	1	0.40	2.5 (0.1, 9.2)	<i>Fitted to CHESS</i>
$ICU_{wR}$	Hospitalised in ICU, leading to recovery	1	0.06	15.6 (0.4, 57.6)	<i>Fitted to CHESS</i>
$ICU_{wD}$	Hospitalised in ICU, leading to death in step-down following ICU	1	0.14	7.0 (0.2, 25.7)	<i>Fitted to CHESS</i>
$ICU_D$	Hospitalised in ICU, leading to death	2	0.17	11.8 (1.4, 32.9)	<i>Fitted to CHESS</i>
$W_R$	Stepdown recovery period after leaving ICU	2	0.16	12.2 (1.5, 34.0)	<i>Fitted to CHESS</i>
$W_D$	Stepdown period before death after leaving ICU	1	0.12	8.1 (0.2, 29.7)	<i>Fitted to CHESS</i>
$R$	Recovered	-	-	-	-
$T_{pre}^{PCR}$	Pre-PCR positive	1	0.33	3.0 (0.1, 11.1)	<i>Omar et al. (16)</i>
$T_{pos}^{PCR}$	True PCR positive	1	0.06	17.5 (0.4, 64.5)	-
$T_{neg}^{PCR}$	True PCR negative	-	-	-	-
$T_{pre}^{sero}$	Pre-seroconversion	1	0.08	13.0 (0.3, 48.0)	<i>Benny et al. (17)</i>
$T_{pos}^{sero}$	True seropositive	-	-	-	-
$T_{neg}^{sero}$	True seronegative	-	-	-	-

214 *Values of fitted parameters are set out in Table S 5.*

215

### 216 1.3.3 Progression of infection and hospitalisation

217 The force of infection,  $\lambda^i(t)$ , for individuals in group  $i \in \{[0,5), \dots, [75,80), [80+)\}$ ,  $CHW, CHR\}$   
 218 depends on time-varying social mixing between age groups and prevalence in all age/care  
 219 home groups:

$$\lambda^i(t) = \sum_j m_{i,j}(t)\Pi_j(t) \quad (1)$$

220

221 where  $m_{i,j}(t)$  is the (symmetric) time-varying person-to-person transmission rate from group  
 222  $j$  to group  $i$ , and  $\Pi_j(t)$  is the number of infectious individuals in group  $j$ , given by:

$$\Pi_j(t) = I_A^j(t) + I_C^j(t) \quad (2)$$

223

224 Broadly, to parameterise  $m_{i,j}(t)$ , we informed mixing in the general population, and between  
 225 the general population and care home workers using POLYMOD (10) via the R package  
 226 *socialmixr* using age-structured regional demography (18).

227 Transmission between different age groups  $(i,j) \in \{[0,5), \dots, [75,80), [80+)\}^2$  was  
 228 parameterised as follows:

$$m_{i,j}(t) = \beta(t)c_{i,j} \quad (3)$$

229 Here  $c_{i,j}$  is the (symmetric) person-to-person contact rate between age group  $i$  and  $j$ , derived  
 230 from pre-pandemic data (10).  $\beta(t)$  is the time-varying transmission rate which encompasses  
 231 both changes over time in transmission efficiency (e.g. due to temperature) and temporal  
 232 changes in the overall level of contacts in the population (due to changes in policy and  
 233 behaviours).

234 We assumed  $\beta(t)$  to be piecewise linear:

$$\beta(t) = \begin{cases} \beta_1, & \text{if } t \leq t_1 \\ \frac{t_i - t}{t_i - t_{i-1}} \beta_{i-1} + \frac{t - t_{i-1}}{t_i - t_{i-1}} \beta_i, & \text{if } t_{i-1} < t \leq t_i, \quad i = 2, \dots, 13 \\ \beta_{13}, & \text{if } t > t_{13} \end{cases} \quad (4)$$

235

236 with 12 change points  $t_i$  corresponding to major announcements and changes in COVID-19  
 237 related policy, as detailed in Table S 3.

238

239

240 *Table S 3: Changepoints for  $\beta(t)$*

Changepoint	Value of $\beta(t)$ at changepoint	Date	Description
$t_1$	$\beta_1$	16/03/20	PM makes speech advising working from home, against non-essential travel (19)
$t_2$	$\beta_2$	23/03/20	PM announces lockdown 1 (20)
$t_3$	$\beta_3$	25/03/20	Lockdown 1 into full effect (21)
$t_4$	$\beta_4$	11/05/20	Initial easing of lockdown 1 (22)
$t_5$	$\beta_5$	15/06/20	Non-essential shops can re-open (23)
$t_6$	$\beta_6$	04/07/20	Restaurants, pubs etc can re-open (24)
$t_7$	$\beta_7$	03/08/20	"Eat out to help out" scheme starts (25)
$t_8$	$\beta_8$	01/09/20	Schools and universities re-open (26)
$t_9$	$\beta_9$	14/09/20	"Rule of six" introduced (27)
$t_{10}$	$\beta_{10}$	14/10/20	Tiered system introduced (28)
$t_{11}$	$\beta_{11}$	31/10/20	Lockdown 2 announced (29)
$t_{12}$	$\beta_{12}$	05/11/20	Lockdown 2 starts (29)

241  
242

243 The contact matrix  $c_{i,j}$  between different age groups  $(i, j) \in \{[0,5), \dots, [75,80), [80+)\}^2$  is  
244 derived from the POLYMOD survey (10) for the United Kingdom using the *socialmixr*  
245 package (18,30), scaling by the local population demography to yield the required person-to-  
246 person daily contact rate matrix.

247 We defined parameters representing transmission rates within care homes (between and  
248 among workers and residents), which were assumed to be constant over time. Parameter  
249  $m_{CHW}$  represents the person-to-person transmission rate among care home workers and  
250 between care home workers and residents;  $m_{CHR}$  represents the person-to-person  
251 transmission rate among care home residents. Hence,

$$m_{CHW,CHW}(t) = m_{CHW,CHR}(t) = m_{CHW} \quad (5)$$

$$m_{CHR,CHR}(t) = m_{CHR} \quad (6)$$

252 Transmission between the general population and care home workers was assumed to be  
253 similar to that within the general population, accounting for the average age of care home  
254 workers, with, for  $i \in \{[0,5), \dots, [75,80), [80+)\}$ ,

$$m_{i,CHW}(t) = \beta(t)c_{i,CHW} \quad (7)$$

255 where  $c_{i,CHW}$  is the mean of  $c_{i,[25,30)}, c_{i,[30,35)}, \dots, c_{i,[60,65)}$  (i.e. of the age groups that the care  
256 home workers are drawn from).

257 Transmission between the general population and care home residents was assumed to be  
258 similar to that between the general population and the 80+ age group, adjusted by a  
259 reduction factor ( $\epsilon$ , which was estimated), such that, for  $i \in \{[0,5), \dots, [75,80), [80+)\}$ ,

$$m_{i,CHR}(t) = \epsilon\beta(t)c_{i,80+} \quad (8)$$

260 These represent contact between visitors from the general community and care home  
261 residents. This might involve a slightly different age profile than the age profile of the contact  
262 made by people in the 80+ age group.

263 1.3.4 Age-varying and time-varying infection progression probabilities

264 Various probabilities of clinical progression within the model are assumed to vary across age  
 265 groups to account for severity of infection varying with age, and some are assumed to vary  
 266 in time in order to model improvements in clinical outcomes, such as those achieved through  
 267 the use of dexamethasone (31).

268 Two probabilities are age-varying but not time-varying, the probability of admission to  
 269 hospital for symptomatic cases, and the probability of death for severe symptomatic cases in  
 270 care homes. These were modelled as follows:

271

$$p_H^i = \psi_H^i p_H^{max} \quad (9)$$

$$p_{G_D}^i = \psi_{G_D}^i p_{G_D}^{max} \quad (10)$$

272

273 where for probability  $p_X^i$ ,  $p_X^{max}$  is the maximum across all groups and  $\psi_X^i$  is the age scaling  
 274 such that  $\psi_X^i = 1$  for the group corresponding to the maximum, against which all other  
 275 groups are scaled.

276 As well as varying with age, four probabilities also vary with time: the probability of  
 277 admission to ICU for hospitalised cases, the probability of death in ICU, the probability of  
 278 death for hospitalised cases not admitted to ICU, and the probability of death in hospital after  
 279 discharge from ICU:

280

$$p_{ICU}^i(t) = \psi_{ICU}^i p_{ICU}^{max} h(\mu_{ICU}, t) \quad (11)$$

$$p_{ICU_D}^i(t) = \psi_{ICU_D}^i p_{ICU_D}^{max} h(\mu_D, t) \quad (12)$$

$$p_{H_D}^i(t) = \psi_{H_D}^i p_{H_D}^{max} h(\mu_D, t) \quad (13)$$

$$p_{W_D}^i(t) = \psi_{W_D}^i p_{W_D}^{max} h(\mu_D, t) \quad (14)$$

281

282 where here for probability  $p_X^i$ ,  $p_X^{max}$  gives the maximum *initial* value across groups and  
 283  $h(\mu, t) = 1$  before April 1<sup>st</sup>,  $h(\mu, t) = \mu < 1$  after June 1<sup>st</sup>, with a linear reduction in between.

284

285 Care home residents with severe disease leading to death are assumed to remain in  
 286 compartment  $G_D$  for 5 days on average before dying (modelled with  $k_{G_D} = 2$  and  $\gamma_{G_D} = 0.4$ ),  
 287 95% range 0.6-13.9 days broadly consistent with durations in (15) and with duration about  
 288 half the length observed in hospital streams (see Figure S 5).

289

290 For care home workers, the age scaling  $\psi_X^{CHR}$  is taken as the mean of the age scalings  $\psi_X^i$   
 291 for  $i \in \{[25,30), [30,35), \dots, [60,65)\}$ . For care home residents, we assume that  $\psi_X^{CHR} =$   
 292  $\psi_X^{[80+)}$ , with the exception of the probability of individual with severe disease requiring  
 293 hospitalisation dying at home (without receiving hospital care), where we assume  $\psi_{G_D}^{CHR} = 1$   
 294 and  $\psi_{G_D}^i = 0$  for all other groups, to effectively allow death outside hospital only for care  
 295 home residents.



296 **1.4 Reproduction number  $R_t$  and effective reproduction number  $R_t^{eff}$**

297 We calculated the reproduction number over time,  $R_t$ , and effective reproduction number  
 298 over time,  $R_t^{eff}$ , using next generation matrix methods (32). The reproduction numbers are  
 299 calculated for the general population, i.e. excluding care home workers and residents. We  
 300 define  $R_t$  as the average number of secondary infections a case infected at time  $t$  would  
 301 generate in a large entirely susceptible population, and  $R_t^{eff}$  as the average number of  
 302 secondary infections generated by a case infected at time  $t$  would accounting for the finite  
 303 population size and potential immunity in the population.

304 To compute the next generation matrix, we calculated the mean duration of infectiousness  
 305  $\Delta_I$ , as

$$\Delta_I = (1 - p_C)\mathbb{E}[\tau_{IA}] + p_C\mathbb{E}[\tau_{IC}] \quad (15)$$

306

307 where parameter and model compartment notations are defined in Table S 2 - Table S 8.  
 308 For this calculation, the expected durations of stay in compartments were adjusted to  
 309 account for the discrete-time nature of the model, via calculating the expected number of  
 310 time-steps (of length  $dt$ ) spent in a given compartment. Note that if in continuous-time a  
 311 compartment duration is  $\tau \sim \text{Erlang}(k, \gamma)$ , then the corresponding discrete-time mean  
 312 duration is:

$$E[\tau] = \frac{k dt}{(1 - e^{-\gamma dt})} \quad (16)$$

313 The next generation matrix was calculated as, for  $(i, j) \in \{[0,5), \dots, [75,80), [80 +)\}^2$ ,

314

$$\text{NGM}_{ij}(t) = m_{ij}(t)\Delta_I N^i \quad (17)$$

315

316 where  $N^i$  is the total population of group  $i$  and  $R_t$  is taken to be the dominant eigenvalue of  
 317  $\text{NGM}(t)$ , while the effective next generation matrix was calculated as:

318

$$\text{NGM}_{ij}^{eff}(t) = m_{ij}(t)\Delta_I S^i(t) \quad (18)$$

319 with  $R_t^{eff}$  taken to be the dominant eigenvalue of  $\text{NGM}^{eff}(t)$ .

320

321 **1.5 Infection severity**

322 Posterior estimates of severity, namely the infection hospitalisation and infection fatality  
 323 ratios, were calculated in each group  $i$  as follows:

324

$$\text{IHR}^i = p_C p_H^i (1 - p_{G_D}^i) \quad (19)$$

$$\text{IFR}^i(t) = p_C p_H^i \left\{ p_{G_D}^i + (1 - p_{G_D}^i) \left( p_{ICU}^i(t) \left( p_{ICU_D}^i(t) + (1 - p_{ICU_D}^i(t)) p_{W_D}^i(t) \right) + (1 - p_{ICU}^i(t)) p_{H_D}^i(t) \right) \right\} \quad (20)$$

325

326 Note that for simplicity the notation we use do refer explicitly to the NHS region of interest.  
 327 We calculated age-aggregated estimates for each region by weighting the age-specific  
 328 severity estimates by the cumulative incidence in that age group. Aggregate estimates for  
 329 England were then calculated by weighting the region-specific estimates by the regional  
 330 attack rates.

331

## 332 1.6 Compartmental model equations

333 To clearly illustrate the model dynamics, we describe a deterministic version of the model in  
 334 differential equations (22)-(57), followed by the stochastic implementation used in the  
 335 analysis. Each compartment is stratified by mixing category  $i \in$   
 336  $\{[0,5), \dots, [75,80), [80 +), CHW, CHR\}$ . Full definitions of compartments and model parameters  
 337 are set out in Table S 2 - Table S 8.

338

$$dS^i(t)/dt = -\lambda^i(t)S^i(t) \quad (21)$$

$$dE^{i,1}(t)/dt = \lambda^i(t)S^i(t) - \gamma_E E^{i,1}(t) \quad (22)$$

$$dE^{i,2}(t)/dt = \gamma_E E^{i,1}(t) - \gamma_E E^{i,2}(t) \quad (23)$$

$$dI_A^i(t)/dt = (1 - p_C)\gamma_E E^{i,2}(t) - \gamma_A I_A^i(t) \quad (24)$$

$$dI_C^i(t)/dt = p_C \gamma_E E^{i,2}(t) - \gamma_C I_C^i(t) \quad (25)$$

$$dG_D^{i,1}(t)/dt = p_H^i p_{G_D}^i \gamma_C I_C^i(t) - \gamma_{G_D} G_D^{i,1}(t) \quad (26)$$

$$dG_D^{i,2}(t)/dt = \gamma_{G_D} G_D^{i,1}(t) - \gamma_{G_D} G_D^{i,2}(t) \quad (27)$$

$$dICU_{pre}^i(t)/dt = p_H^i (1 - p_{G_D}^i) (1 - p^*(t)) p_{ICU}^i(t) \gamma_C I_C^i(t) - (\gamma_{ICU_{pre}} + \gamma_U) ICU_{pre}^i(t) \quad (28)$$

$$dICU_{pre^*}^i(t)/dt = p_H^i (1 - p_{G_D}^i) p^*(t) p_{ICU}^i(t) \gamma_C I_C^i(t) - \gamma_{ICU_{pre}} ICU_{pre^*}^i(t) + \gamma_U ICU_{pre}^i(t) \quad (29)$$

$$dICU_{W_R}^i(t)/dt = (1 - p_{ICU_D}^i(t)) (1 - p_{W_D}^i(t)) \gamma_{ICU_{pre}} ICU_{pre}^i(t) - (\gamma_{ICU_{W_R}} + \gamma_U) ICU_{W_R}^i(t) \quad (30)$$

$$dICU_{W_R^*}^i(t)/dt = (1 - p_{ICU_D}^i(t)) (1 - p_{W_D}^i(t)) \gamma_{ICU_{pre}} ICU_{pre^*}^i(t) - \gamma_{ICU_{W_R}} ICU_{W_R^*}^i(t) + \gamma_U ICU_{W_R}^i(t) \quad (31)$$

$$dICU_{W_D}^i(t)/dt = (1 - p_{ICU_D}^i(t)) p_{W_D}^i(t) \gamma_{ICU_{pre}} ICU_{pre}^i(t) - (\gamma_{ICU_{W_D}} + \gamma_U) ICU_{W_D}^i(t) \quad (32)$$

$$dICU_{W_D^*}^i(t)/dt = (1 - p_{ICU_D}^i(t)) p_{W_D}^i(t) \gamma_{ICU_{pre}} ICU_{pre^*}^i(t) - \gamma_{ICU_{W_D}} ICU_{W_D^*}^i(t) + \gamma_U ICU_{W_D}^i(t) \quad (33)$$

$$dICU_D^{i,1}(t)/dt = p_{ICU_D}^i(t) \gamma_{ICU_{pre}} ICU_{pre}^i(t) - (\gamma_{ICU_D} + \gamma_U) ICU_D^{i,1}(t) \quad (34)$$

$$dICU_D^{i,2}(t)/dt = \gamma_{ICU_D} ICU_D^{i,1}(t) - (\gamma_{ICU_D} + \gamma_U) ICU_D^{i,2}(t) \quad (35)$$

$$dICU_{D^*}^{i,1}(t)/dt = p_{ICU_D}^i(t) \gamma_{ICU_{pre}} ICU_{pre^*}^i(t) - \gamma_{ICU_D} ICU_{D^*}^{i,1}(t) + \gamma_U ICU_D^{i,1}(t) \quad (36)$$

$$dICU_{D^*}^{i,2}(t)/dt = \gamma_{ICU_D} ICU_{D^*}^{i,1}(t) - \gamma_{ICU_D} ICU_{D^*}^{i,2}(t) + \gamma_U ICU_D^{i,2}(t) \quad (37)$$

$$dW_R^{i,1}(t)/dt = \gamma_{ICU_{WR}} ICU_{WR}^i(t) - (\gamma_{WR} + \gamma_U) W_R^{i,1}(t) \quad (38)$$

$$dW_R^{i,2}(t)/dt = \gamma_{WR} W_R^{i,1}(t) - (\gamma_{WR} + \gamma_U) W_R^{i,2}(t) \quad (39)$$

$$dW_{R^*}^{i,1}(t)/dt = \gamma_{ICU_{WR^*}} ICU_{WR^*}^i(t) - \gamma_{WR} W_{R^*}^{i,1}(t) + \gamma_U W_{R^*}^{i,1}(t) \quad (40)$$

$$dW_{R^*}^{i,2}(t)/dt = \gamma_{WR} W_{R^*}^{i,1}(t) - \gamma_{WR} W_{R^*}^{i,2}(t) + \gamma_U W_{R^*}^{i,2}(t) \quad (41)$$

$$dW_D^i(t)/dt = \gamma_{ICU_{WD}} ICU_{WD}^i(t) - (\gamma_{WD} + \gamma_U) W_D^i(t) \quad (42)$$

$$dW_{D^*}^i(t)/dt = \gamma_{ICU_{WD^*}} ICU_{WD^*}^i(t) - \gamma_{WD} W_{D^*}^i(t) + \gamma_U W_{D^*}^i(t) \quad (43)$$

$$dH_R^i(t)/dt = p_H^i (1 - p_{GD}^i) (1 - p^*(t)) (1 - p_{ICU}^i(t)) (1 - p_{HD}^i(t)) \gamma_C I_C^i(t) - (\gamma_{HR} + \gamma_U) H_R^i(t) \quad (44)$$

$$dH_{R^*}^i(t)/dt = p_H^i (1 - p_{GD}^i) p^*(t) (1 - p_{ICU}^i(t)) (1 - p_{HD}^i(t)) \gamma_C I_C^i(t) + \gamma_U H_{R^*}^i(t) - \gamma_{HR} H_{R^*}^i(t) \quad (45)$$

$$dH_D^{i,1}(t)/dt = p_H^i (1 - p_{GD}^i) (1 - p^*(t)) (1 - p_{ICU}^i(t)) p_{HD}^i(t) \gamma_C I_C^i(t) - (\gamma_{HD} + \gamma_U) H_D^{i,1}(t) \quad (46)$$

$$dH_D^{i,2}(t)/dt = \gamma_{HD} H_D^{i,1}(t) - (\gamma_{HD} + \gamma_U) H_D^{i,2}(t) \quad (47)$$

$$dH_{D^*}^{i,1}(t)/dt = p_H^i (1 - p_{GD}^i) p^*(t) (1 - p_{ICU}^i(t)) p_{HD}^i(t) \gamma_C I_C^i(t) + \gamma_U H_{D^*}^{i,1}(t) - \gamma_{HD} H_{D^*}^{i,1}(t) \quad (48)$$

$$dH_{D^*}^{i,2}(t)/dt = \gamma_{HD} H_{D^*}^{i,1}(t) - \gamma_{HD} H_{D^*}^{i,2}(t) + \gamma_U H_{D^*}^{i,2}(t) \quad (49)$$

$$dR^i(t)/dt = \gamma_A I_A^i(t) + (1 - p_H^i) \gamma_C I_C^i(t) + \gamma_{HR} (H_R^i(t) + H_{R^*}^i(t)) + \gamma_{WR} (W_R^i(t) + W_{R^*}^i(t)) \quad (50)$$

$$dT_{seropre}^i(t)/dt = \gamma_E E^{i,2}(t) - \gamma_{seropre} T_{seropre}^i(t) \quad (51)$$

$$dT_{seropos}^i(t)/dt = p_{seropos} \gamma_{seropre} T_{PCRpre}^i(t) \quad (52)$$

$$dT_{seroneg}^i(t)/dt = (1 - p_{seropos}) \gamma_{seropre} T_{PCRpre}^i(t) \quad (53)$$

$$dT_{PCRpre}^i(t)/dt = \lambda^i(t) S^i(t) - \gamma_{PCRpre} T_{PCRpre}^i(t) \quad (54)$$

$$dT_{PCRpos}^i(t)/dt = \gamma_{PCRpre} T_{PCRpre}^i(t) - \gamma_{PCRpos} T_{PCRpos}^i(t) \quad (55)$$

$$dT_{PCRneg}^i(t)/dt = \gamma_{PCRpos} T_{PCRpos}^i(t) \quad (56)$$

339

340 We used the tau-leap method (33) to create a stochastic, time-discretised version of the  
 341 model described in equations (58-162), taking four update steps per day. The process was  
 342 initialised with ten asymptomatic infectious individuals aged 15-19 on the epidemic start date  
 343  $t_0$ , a parameter we estimate. For each time step, the model iterated through the procedure  
 344 described below. In the following, we introduce a small abuse of notation: for transitions  
 345 involving multiple onward compartments (e.g transition from compartment  $E$  to  
 346 compartments  $I_A$  or  $I_C$ ), for conciseness, we write

$$(d_{E,I_A}^i, d_{E,I_C}^i) \sim \text{Multinom}(E^{i,2}(t), q_{E,I_A}^i, q_{E,I_C}^i)$$

347 instead of

$$(d_{E,I_A}^i, d_{E,I_C}^i, d_{nomove}^i) \sim \text{Multinom}(E^{i,2}(t), q_{E,I_A}^i, q_{E,I_C}^i, 1 - \sum_{x \in \{I_A, I_C\}} q_{E,x}^i)$$

348 where  $d_{nomove}^i$  is a dummy variable counting the number of individuals remaining in compartment  
 349  $E^{i,2}$ .

350 Using this convention, transition variables are drawn from the following distributions, with  
 351 probabilities defined below:

$$d_{S,E}^i \sim \text{Binom} \left( S^i(t), 1 - e^{-\lambda^i(t)dt} \right) \quad (57)$$

$$d_{E,E}^i \sim \text{Binom} \left( E^{i,1}(t), 1 - e^{-\gamma_E dt} \right) \quad (58)$$

$$(q_{E,IA}^i, q_{E,IC}^i) = ((1 - p_C)(1 - e^{-\gamma_E dt}), p_C(1 - e^{-\gamma_E dt})) \quad (59)$$

$$(d_{E,IA}^i, d_{E,IC}^i) \sim \text{Multinom} \left( E^{i,2}(t), q_{E,IA}^i, q_{E,IC}^i \right) \quad (60)$$

$$d_{IA,R}^i \sim \text{Binom} \left( I_A^i(t), 1 - e^{-\gamma_A dt} \right) \quad (61)$$

$$q_{IC,GD}^i = p_H^i p_{GD}^i (1 - e^{-\gamma_C dt}) \quad (62)$$

$$q_{IC,R}^i = (1 - p_H^i)(1 - e^{-\gamma_C dt}) \quad (63)$$

$$q_{IC,ICU_{pre}}^i = p_H^i (1 - p_{GD}^i) (1 - p^*(t)) p_{ICU}^i(t) (1 - e^{-\gamma_C dt}) \quad (64)$$

$$q_{IC,ICU_{pre}^*}^i = p_H^i (1 - p_{GD}^i) p^*(t) p_{ICU}^i(t) (1 - e^{-\gamma_C dt}) \quad (65)$$

$$q_{IC,HR}^i = p_H^i (1 - p_{GD}^i) (1 - p^*(t)) (1 - p_{ICU}^i(t)) (1 - p_{HD}^i(t)) (1 - e^{-\gamma_C dt}) \quad (66)$$

$$q_{IC,HR}^{i*} = p_H^i (1 - p_{GD}^i) p^*(t) (1 - p_{ICU}^i(t)) (1 - p_{HD}^i(t)) (1 - e^{-\gamma_C dt}) \quad (67)$$

$$q_{IC,HD}^i = p_H^i (1 - p_{GD}^i) (1 - p^*(t)) (1 - p_{ICU}^i(t)) p_{HD}^i(t) (1 - e^{-\gamma_C dt}) \quad (68)$$

$$q_{IC,HD}^{i*} = p_H^i (1 - p_{GD}^i) p^*(t) (1 - p_{ICU}^i(t)) p_{HD}^i(t) (1 - e^{-\gamma_C dt}) \quad (69)$$

$$(d_{IC,GD}^i, \dots, d_{IC,HD}^{i*}) \sim \text{Multinom} \left( I_C^i(t), q_{IC,GD}^i, \dots, q_{IC,HD}^{i*} \right) \quad (70)$$

$$d_{GD,GD}^i \sim \text{Binom} \left( G_D^{i,1}(t), 1 - e^{-\gamma_{GD} dt} \right) \quad (71)$$

$$d_{GD,D}^i \sim \text{Binom} \left( G_D^{i,2}(t), 1 - e^{-\gamma_{GD} dt} \right) \quad (72)$$

$$q_{ICU_{pre},ICU_{WR}}^i = (1 - p_{ICU_D}^i(t)) (1 - p_{WD}^i(t)) (1 - e^{-\gamma_{ICU_{pre}} dt}) e^{-\gamma_{UD} dt} \quad (73)$$

$$q_{ICU_{pre},ICU_{WR}^*}^i = (1 - p_{ICU_D}^i(t)) (1 - p_{WD}^i(t)) (1 - e^{-\gamma_{ICU_{pre}} dt}) (1 - e^{-\gamma_{UD} dt}) \quad (74)$$

$$q_{ICU_{pre},ICU_{WD}}^i = (1 - p_{ICU_D}^i(t)) p_{WD}^i(t) (1 - e^{-\gamma_{ICU_{pre}} dt}) e^{-\gamma_{UD} dt} \quad (75)$$

$$q_{ICU_{pre},ICU_{WD}^*}^i = (1 - p_{ICU_D}^i(t)) p_{WD}^i(t) (1 - e^{-\gamma_{ICU_{pre}} dt}) (1 - e^{-\gamma_{UD} dt}) \quad (76)$$

$$q_{ICU_{pre},ICU_D}^i = p_{ICU_D}^i(t) (1 - e^{-\gamma_{ICU_{pre}} dt}) e^{-\gamma_{UD} dt} \quad (77)$$

$$q_{ICU_{pre},ICU_D}^{i*} = p_{ICU_D}^i(t) (1 - e^{-\gamma_{ICU_{pre}} dt}) (1 - e^{-\gamma_{UD} dt}) \quad (78)$$

$$q_{ICU_{pre},ICU_{pre}^*}^i = e^{-\gamma_{ICU_{pre}} dt} (1 - e^{-\gamma_{UD} dt}) \quad (79)$$

$$(d_{ICU_{pre},ICU_{WR}}^i, \dots, d_{ICU_{pre},ICU_{pre}^*}^i) \sim \text{Multinom} \left( ICU_{pre}^i(t), q_{ICU_{pre},ICU_{WR}}^i, \dots, q_{ICU_{pre},ICU_{pre}^*}^i \right) \quad (80)$$

$$q_{ICU_{pre}^*,ICU_{WR}^*}^i = (1 - p_{ICU_D}^i(t)) (1 - p_{WD}^i(t)) (1 - e^{-\gamma_{ICU_{pre}} dt}) \quad (81)$$

$$q_{ICU_{pre}^*,ICU_{WD}^*}^i = (1 - p_{ICU_D}^i(t)) p_{WD}^i(t) (1 - e^{-\gamma_{ICU_{pre}} dt}) \quad (82)$$

$$q_{ICU_{pre}^*,ICU_D}^{i*} = p_{ICU_D}^i(t) (1 - e^{-\gamma_{ICU_{pre}} dt}) \quad (83)$$

$$(d_{ICU_{pre}^*,ICU_{WR}^*}^i, \dots, d_{ICU_{pre}^*,ICU_D}^{i*}) \sim \text{Multinom} \left( ICU_{pre}^{i*}(t), q_{ICU_{pre}^*,ICU_{WR}^*}^i, \dots, q_{ICU_{pre}^*,ICU_D}^{i*} \right) \quad (84)$$

$$q_{H_D, H_D}^i = (1 - e^{-\gamma_{H_D} dt}) e^{-\gamma_U dt} \quad (85)$$

$$q_{H_D, H_{D^*}}^{i,1,1} = e^{-\gamma_{H_D} dt} (1 - e^{-\gamma_U dt}) \quad (86)$$

$$q_{H_D, H_{D^*}}^{i,1,2} = (1 - e^{-\gamma_{H_D} dt}) (1 - e^{-\gamma_U dt}) \quad (87)$$

$$(d_{H_D, H_D}^i, d_{H_D, H_{D^*}}^{i,1,1}, d_{H_D, H_{D^*}}^{i,1,2}) \sim \text{Multinom} (H_D^{i,1}(t), q_{H_D, H_D}^i, q_{H_D, H_{D^*}}^{i,1,1}, q_{H_D, H_{D^*}}^{i,1,2}) \quad (88)$$

$$d_{H_{D^*}, H_{D^*}}^i \sim \text{Binom} (H_{D^*}^{i,1}(t), 1 - e^{-\gamma_{H_D} dt}) \quad (89)$$

$$(d_{H_D, D}^i, d_{H_D, H_{D^*}}^{i,2,2}) \sim \text{Multinom} (H_D^{i,2}(t), 1 - e^{-\gamma_{H_D} dt}, e^{-\gamma_{H_D} dt} (1 - e^{-\gamma_U dt})) \quad (90)$$

$$d_{H_{D^*}, D}^i \sim \text{Binom} (H_{D^*}^{i,2}(t), 1 - e^{-\gamma_{H_D} dt}) \quad (91)$$

$$(d_{H_R, R}^i, d_{H_R, H_{R^*}}^i) \sim \text{Multinom} (H_R^i(t), 1 - e^{-\gamma_{H_R} dt}, e^{-\gamma_{H_R} dt} (1 - e^{-\gamma_U dt})) \quad (92)$$

$$d_{H_{R^*}, R}^i \sim \text{Binom} (H_{R^*}^i(t), 1 - e^{-\gamma_{H_R} dt}) \quad (93)$$

$$q_{ICU_{W_R}, W_R}^i = (1 - e^{-\gamma_{ICU_{W_R}} dt}) e^{-\gamma_U dt} \quad (94)$$

$$q_{ICU_{W_R}, ICU_{W_{R^*}}}^i = e^{-\gamma_{ICU_{W_R}} dt} (1 - e^{-\gamma_U dt}) \quad (95)$$

$$q_{ICU_{W_R}, W_{R^*}}^i = (1 - e^{-\gamma_{ICU_{W_R}} dt}) (1 - e^{-\gamma_U dt}) \quad (96)$$

$$(d_{ICU_{W_R}, W_R}^i, \dots, d_{ICU_{W_R}, W_{R^*}}^i) \sim \text{Multinom} (ICU_{W_R}^i(t), q_{ICU_{W_R}, W_R}^i, \dots, q_{ICU_{W_R}, W_{R^*}}^i) \quad (97)$$

$$d_{ICU_{W_{R^*}}, W_{R^*}}^i \sim \text{Binom} (ICU_{W_{R^*}}^i(t), 1 - e^{-\gamma_{ICU_{W_R}} dt}) \quad (98)$$

$$q_{ICU_{W_D}, W_D}^i = (1 - e^{-\gamma_{ICU_{W_D}} dt}) e^{-\gamma_U dt} \quad (99)$$

$$q_{ICU_{W_D}, ICU_{W_{D^*}}}^i = e^{-\gamma_{ICU_{W_D}} dt} (1 - e^{-\gamma_U dt}) \quad (100)$$

$$q_{ICU_{W_D}, W_{D^*}}^i = (1 - e^{-\gamma_{ICU_{W_D}} dt}) (1 - e^{-\gamma_U dt}) \quad (101)$$

$$(d_{ICU_{W_D}, W_D}^i, \dots, d_{ICU_{W_D}, W_{D^*}}^i) \sim \text{Multinom} (ICU_{W_D}^i(t), q_{ICU_{W_D}, W_D}^i, \dots, q_{ICU_{W_D}, W_{D^*}}^i) \quad (102)$$

$$d_{ICU_{W_{D^*}}, W_{D^*}}^i \sim \text{Binom} (ICU_{W_{D^*}}^i(t), 1 - e^{-\gamma_{ICU_{W_D}} dt}) \quad (103)$$

$$q_{ICU_D, ICU_D}^i = (1 - e^{-\gamma_{ICU_D} dt}) e^{-\gamma_U dt} \quad (104)$$

$$q_{ICU_D, ICU_{D^*}}^{i,1,1} = e^{-\gamma_{ICU_D} dt} (1 - e^{-\gamma_U dt}) \quad (105)$$

$$q_{ICU_D, ICU_{D^*}}^{i,1,2} = (1 - e^{-\gamma_{ICU_D} dt}) (1 - e^{-\gamma_U dt}) \quad (106)$$

$$(d_{ICU_D, ICU_D}^i, d_{ICU_D, ICU_{D^*}}^{i,1,1}, d_{ICU_D, ICU_{D^*}}^{i,1,2}) \sim \text{Multinom} (ICU_D^{i,1}(t), q_{ICU_D, ICU_D}^i, q_{ICU_D, ICU_{D^*}}^{i,1,1}, q_{ICU_D, ICU_{D^*}}^{i,1,2}) \quad (107)$$

$$d_{ICU_{D^*}, ICU_{D^*}}^i \sim \text{Binom} (ICU_{D^*}^{i,1}(t), 1 - e^{-\gamma_{ICU_D} dt}) \quad (108)$$

$$(d_{ICU_D, D}^i, d_{ICU_D, ICU_{D^*}}^{i,2,2}) \sim \text{Multinom} (ICU_D^{i,2}(t), 1 - e^{-\gamma_{ICU_D} dt}, e^{-\gamma_{ICU_D} dt} (1 - e^{-\gamma_U dt})) \quad (109)$$

$$d_{ICU_{D^*}, D}^i \sim \text{Binom} (ICU_{D^*}^{i,2}(t), 1 - e^{-\gamma_{ICU_D} dt}) \quad (110)$$

$$q_{W_R, W_R}^i = (1 - e^{-\gamma_{W_R} dt}) e^{-\gamma_U dt} \quad (111)$$

$$q_{W_R, W_{R^*}}^{i,1,1} = e^{-\gamma_{W_R} dt} (1 - e^{-\gamma_U dt}) \quad (112)$$

$$q_{W_R, W_{R^*}}^{i,1,2} = (1 - e^{-\gamma_{W_R} dt}) (1 - e^{-\gamma_U dt}) \quad (113)$$

$$\left( d_{W_R, W_R}^i, d_{W_R, W_{R^*}}^{i,1,1}, d_{W_R, W_{R^*}}^{i,1,2} \right) \sim \text{Multinom} \left( W_R^{i,1}(t), q_{W_R, W_R}^i, q_{W_R, W_{R^*}}^{i,1,1}, q_{W_R, W_{R^*}}^{i,1,2} \right) \quad (114)$$

$$d_{W_{R^*}, W_{R^*}}^i \sim \text{Binom} \left( W_{R^*}^{i,1}(t), 1 - e^{-\gamma W_R dt} \right) \quad (115)$$

$$\left( d_{W_R, R}^i, d_{W_R, W_{R^*}}^{i,2,2} \right) \sim \text{Multinom} \left( W_R^{i,2}(t), 1 - e^{-\gamma W_R dt}, e^{-\gamma W_R dt} (1 - e^{-\gamma U dt}) \right) \quad (116)$$

$$d_{W_{R^*}, R}^i \sim \text{Binom} \left( W_{R^*}^{i,2}(t), 1 - e^{-\gamma W_R dt} \right) \quad (117)$$

$$\left( d_{W_D, D}^i, d_{W_D, W_{D^*}}^i \right) \sim \text{Multinom} \left( W_D^i(t), 1 - e^{-\gamma W_D dt}, e^{-\gamma W_D dt} (1 - e^{-\gamma U dt}) \right) \quad (118)$$

$$d_{W_{D^*}, D}^i \sim \text{Binom} \left( W_{D^*}^i(t), 1 - e^{-\gamma W_D dt} \right) \quad (119)$$

$$\left( d_{W_D, D}^i, d_{W_D, W_{D^*}}^i \right) \sim \text{Multinom} \left( W_D^i(t), 1 - e^{-\gamma W_D dt}, e^{-\gamma W_D dt} (1 - e^{-\gamma U dt}) \right) \quad (120)$$

$$q_{T_{seropre}, T_{seropos}}^i = p_{seropos} (1 - e^{-\gamma_{seropre} dt}) \quad (121)$$

$$q_{T_{seropre}, T_{seroneg}}^i = (1 - p_{seropos}) (1 - e^{-\gamma_{seropre} dt}) \quad (122)$$

$$\left( d_{T_{seropre}, T_{seropos}}^i, d_{T_{seropre}, T_{seroneg}}^i \right) \sim \text{Multinom} \left( T_{seropre}^i(t), q_{T_{seropre}, T_{seropos}}^i, q_{T_{seropre}, T_{seroneg}}^i \right) \quad (123)$$

$$d_{T_{PCRpre}, T_{PCRpos}}^i \sim \text{Binom} \left( T_{PCRpre}^i(t), 1 - e^{-\gamma_{PCRpre} dt} \right) \quad (124)$$

$$d_{T_{PCRpos}, T_{PCRneg}}^i \sim \text{Binom} \left( T_{PCRpos}^i(t), 1 - e^{-\gamma_{PCRpos} dt} \right) \quad (125)$$

353

354 Model compartments were then updated as follows:

355

$$S^i(t + dt) := S^i(t) - d_{S,E}^i \quad (126)$$

$$E^{i,1}(t + dt) := E^{i,1}(t) + d_{S,E}^i - d_{E,E}^i \quad (127)$$

$$E^{i,2}(t + dt) := E^{i,2}(t) + d_{E,E}^i - d_{E,IA}^i - d_{E,IC}^i \quad (128)$$

$$I_A^i(t + dt) := I_A^i(t) + d_{E,IA}^i - d_{IA,R}^i \quad (129)$$

$$I_C^i(t + dt) := I_C^i(t) + d_{E,IC}^i - d_{IC,GD}^i - d_{IC,R}^i - d_{IC,ICUpre}^i - d_{IC,ICUpre^*}^i - d_{IC,HR}^i - d_{IC,HR^*}^i - d_{IC,HD}^i - d_{IC,HD^*}^i \quad (130)$$

$$G_D^{i,1}(t + dt) := G_D^{i,1}(t) + d_{IC,GD}^i - d_{GD,GD}^i \quad (131)$$

$$G_D^{i,2}(t + dt) := G_D^{i,2}(t) + d_{GD,GD}^i - d_{GD,D}^i \quad (132)$$

$$ICU_{pre}^i(t + dt) := ICU_{pre}^i(t) + d_{IC,ICUpre}^i - d_{ICUpre,ICUWR}^i - d_{ICUpre,ICUWD}^i - d_{ICUpre,ICUD}^i - d_{ICUpre,ICUpre^*}^i - d_{ICUpre,ICUWR^*}^i - d_{ICUpre,ICUWD^*}^i - d_{ICUpre,ICUD^*}^i \quad (133)$$

$$ICU_{pre^*}^i(t + dt) := ICU_{pre^*}^i(t) + d_{IC,ICUpre^*}^i - d_{ICUpre^*,ICUWD^*}^i - d_{ICUpre^*,ICUWR^*}^i - d_{ICUpre^*,ICUD^*}^i \quad (134)$$

$$ICU_{WR}^i(t + dt) := ICU_{WR}^i(t) + d_{ICUpre,ICUWR}^i - d_{ICUWR,WR}^i - d_{ICUWR,ICUWR^*}^i - d_{ICUWR,WR^*}^i \quad (135)$$

$$ICU_{WR^*}^i(t + dt) := ICU_{WR^*}^i(t) + d_{ICUpre^*,ICUWR^*}^i + d_{ICUWR,ICUWR^*}^i + d_{ICUpre,ICUWR^*}^i - d_{ICUWR^*,WR^*}^i \quad (136)$$

$$ICU_{WD}^i(t + dt) := ICU_{WD}^i(t) + d_{ICUpre,ICUWD}^i - d_{ICUWD,WD}^i - d_{ICUWD,ICUWD^*}^i - d_{ICUWD,WD^*}^i \quad (137)$$

$$ICU_{W_D^*}^i(t+dt) := ICU_{W_D^*}^i(t) + d_{ICU_{pre^*,ICU_{W_D^*}}^i} + d_{ICU_{W_D^*,ICU_{W_D^*}}^i} + d_{ICU_{pre,ICU_{W_D^*}}^i} - d_{ICU_{W_D^*,W_D^*}^i} \quad (138)$$

$$ICU_D^{i,1}(t+dt) := ICU_D^{i,1}(t) + d_{ICU_{pre,ICU_D}^i} - d_{ICU_D,ICU_D}^i - d_{ICU_D,ICU_D^*}^{i,1,1} - d_{ICU_D,ICU_D^*}^{i,1,2} \quad (139)$$

$$ICU_D^{i,2}(t+dt) := ICU_D^{i,2}(t) + d_{ICU_D,ICU_D}^i - d_{ICU_D,D}^i - d_{ICU_D,ICU_D^*}^{i,2,2} \quad (140)$$

$$ICU_{D^*}^{i,1}(t+dt) := ICU_{D^*}^{i,1}(t) + d_{ICU_{pre^*,ICU_{D^*}}^i} + d_{ICU_D,ICU_{D^*}}^{i,1,1} + d_{ICU_{pre,ICU_{D^*}}^i} - d_{ICU_{D^*,ICU_{D^*}}^i} \quad (141)$$

$$ICU_{D^*}^{i,2}(t+dt) := ICU_{D^*}^{i,2}(t) + d_{ICU_{D^*,ICU_{D^*}}^i} + d_{ICU_D,ICU_{D^*}}^{i,1,2} + d_{ICU_D,ICU_{D^*}}^{i,2,2} - d_{ICU_{D^*,D}^i} \quad (142)$$

$$W_R^{i,1}(t+dt) := W_R^{i,1}(t) + d_{ICU_{W_R,W_R}^i} - d_{W_R,W_R}^i - d_{W_R,W_R^*}^{i,1,1} - d_{W_R,W_R^*}^{i,1,2} \quad (143)$$

$$W_R^{i,2}(t+dt) := W_R^{i,2}(t) + d_{W_R,W_R}^i - d_{W_R,R}^i - d_{W_R,W_R^*}^{i,2,2} \quad (144)$$

$$W_{R^*}^{i,1}(t+dt) := W_{R^*}^{i,1}(t) + d_{ICU_{W_{R^*},W_{R^*}}^i} + d_{W_R,W_{R^*}}^{i,1,1} + d_{ICU_{W_R,W_{R^*}}^i} - d_{W_{R^*},W_{R^*}}^i \quad (145)$$

$$W_{R^*}^{i,2}(t+dt) := W_{R^*}^{i,2}(t) + d_{W_{R^*},W_{R^*}}^i + d_{W_R,W_{R^*}}^{i,2,2} + d_{W_R,W_{R^*}}^{i,1,2} - d_{W_{R^*},R}^i \quad (146)$$

$$W_D^i(t+dt) := W_D^i(t) + d_{ICU_{W_D,W_D}^i} - d_{W_D,D}^i - d_{W_D,W_D^*}^i \quad (147)$$

$$W_{D^*}^i(t+dt) := W_{D^*}^i(t) + d_{ICU_{W_{D^*},W_{D^*}}^i} + d_{W_D,W_{D^*}}^i + d_{ICU_{W_D,W_{D^*}}^i} - d_{W_{D^*},D}^i \quad (148)$$

$$H_D^{i,1}(t+dt) := H_D^{i,1}(t) + d_{I_C,H_D}^i - d_{H_D,H_D}^i - d_{H_D,H_D^*}^{i,1,1} - d_{H_D,H_D^*}^{i,1,2} \quad (149)$$

$$H_D^{i,2}(t+dt) := H_D^{i,2}(t) + d_{H_D,H_D}^i - d_{H_D,D}^i - d_{H_D,H_D^*}^{i,2,2} \quad (150)$$

$$H_{D^*}^{i,1}(t+dt) := H_{D^*}^{i,1}(t) + d_{I_C,H_{D^*}}^i + d_{H_D,H_{D^*}}^{i,1,1} - d_{H_{D^*},H_{D^*}}^i \quad (151)$$

$$H_{D^*}^{i,2}(t+dt) := H_{D^*}^{i,2}(t) + d_{H_{D^*},H_{D^*}}^i + d_{H_D,H_{D^*}}^{i,2,2} + d_{H_D,H_{D^*}}^{i,1,2} - d_{H_{D^*},D}^i \quad (152)$$

$$H_R^i(t+dt) := H_R^i(t) + d_{I_C,H_R}^i - d_{H_R,R}^i - d_{H_R,H_R^*}^i \quad (153)$$

$$H_{R^*}^i(t+dt) := H_{R^*}^i(t) + d_{I_C,H_{R^*}}^i + d_{H_R,H_{R^*}}^i - d_{H_{R^*},R}^i \quad (154)$$

$$R^i(t+dt) := R^i(t) + d_{I_A,R}^i + d_{I_C,R}^i + d_{H_R,R}^i + d_{H_{R^*},R}^i + d_{W_R,R}^i + d_{W_{R^*},R}^i \quad (155)$$

$$T_{seropre}^i(t+dt) := T_{seropre}^i(t) + d_{E,I_A}^i + d_{E,I_C}^i - d_{T_{seropre},T_{seropos}}^i - d_{T_{seropre},T_{seroneg}}^i \quad (156)$$

$$T_{seropos}^i(t+dt) := T_{seropos}^i(t) + d_{T_{seropre},T_{seropos}}^i \quad (157)$$

$$T_{seroneg}^i(t+dt) := T_{seroneg}^i(t) + d_{T_{seropre},T_{seroneg}}^i \quad (158)$$

$$T_{PCRpre}^i(t+dt) := T_{PCRpre}^i(t) + d_{S,E}^i - d_{T_{PCRpre},T_{PCRpos}}^i \quad (159)$$

$$T_{PCRpos}^i(t+dt) := T_{PCRpos}^i(t) + d_{T_{PCRpre},T_{PCRpos}}^i - d_{T_{PCRpos},T_{PCRneg}}^i \quad (160)$$

$$T_{PCRneg}^i(t+dt) := T_{PCRneg}^i(t) + d_{T_{PCRpos},T_{PCRneg}}^i \quad (161)$$

356

## 357 1.7 Observation process

358 To describe the epidemic in each NHS region, we fitted our model to time series data on  
 359 hospital admissions, hospital ward occupancy (both in general beds and in ICU beds),  
 360 deaths in hospitals, deaths in care homes, population serological surveys and PCR testing  
 361 data (section 1.1 and Table S 1).

362 *1.7.1 Notation for distributions used in this section*

363 If  $Y \sim \text{NegBinom}(m, \kappa)$ , then  $Y$  follows a negative binomial distribution with mean  $m$  and  
 364 shape  $\kappa$ , such that

365

$$P(Y = y) = \frac{\Gamma(\kappa + y)}{y! \Gamma(\kappa)} \left(\frac{\kappa}{\kappa + m}\right)^\kappa \left(\frac{m}{\kappa + m}\right)^y \quad (162)$$

366

367 where  $\Gamma(x)$  is the gamma function. The variance of  $Y$  is  $m + \frac{m^2}{\kappa}$ .

368 If  $Z \sim \text{BetaBinom}(n, \omega, \rho)$ , then  $Z$  follows a beta-binomial distribution with size  $n$ , mean  
 369 probability  $\omega$  and overdispersion parameter  $\rho$ , such that

370

$$P(Z = z) = \binom{n}{z} \frac{B(z + a, n - z + b)}{B(a, b)} \quad (163)$$

371

372 where  $a = \omega \left(\frac{1-\rho}{\rho}\right)$ ,  $b = (1 - \omega) \left(\frac{1-\rho}{\rho}\right)$  and  $B(a, b)$  is the beta function. The mean of  $Z$  is  $n\omega$   
 373 and the variance is  $n\omega(1 - \omega)[1 + (n - 1)\rho]$ .

374

375 *1.7.2 Hospital admissions and new diagnoses in hospital*

376 We represented the daily number of confirmed COVID-19 hospital admissions and new  
 377 diagnoses for existing hospitalised cases,  $Y_{adm}(t)$ , as the observed realisations of an  
 378 underlying hidden Markov process,  $X_{adm}(t)$ , defined as:

379

$$X_{adm}(t) := \sum_i \left( \sum_{j \in \{H_R^*, H_D^*, ICU_{pre}^*\}} d_{i,j}^i + \sum_{j \in \{H_R, ICU_{pre}, ICU_{W_R}, ICU_{W_D}, W_D\}} d_{j,j^*}^i \right) + d_{H_D, H_D^*}^{i,1,1} + d_{H_D, H_D^*}^{i,1,2} + \quad (164)$$

$$d_{H_D, H_D^*}^{i,2,2} + d_{ICU_D, ICU_D^*}^{i,1,1} + d_{ICU_D, ICU_D^*}^{i,1,2} + d_{ICU_D, ICU_D^*}^{i,2,2} + d_{W_R, W_R^*}^{i,1,1} + d_{W_R, W_R^*}^{i,1,2} +$$

$$d_{W_R, W_R^*}^{i,2,2} + d_{ICU_{pre}, ICU_{W_R^*}}^i + d_{ICU_{pre}, ICU_{W_D^*}}^i + d_{ICU_{pre}, ICU_{D^*}}^i + d_{ICU_{pre}, ICU_{D^*}}^i + d_{ICU_{W_D^*}, W_D^*}^i + d_{ICU_{W_R^*}, W_R^*}^i$$

380

381 Which was related to the data via a reporting distribution:

382

$$Y_{adm}(t) \sim \text{NegBinom}(X_{adm}(t), \kappa_{adm}) \quad (165)$$

383

384 We allow for overdispersion in the observation process to account for noise in the underlying  
 385 data streams, for example due to day-of-week effects on data collection. We adopt  $\kappa = 2$  for  
 386 all NHSE data streams, so that they contribute equal weight to the overall likelihood.  
 387

388 *1.7.3 Hospital bed occupancy by confirmed COVID-19 cases*

389 The model predicted general hospital bed occupancy by confirmed COVID-19 cases,  
 390  $X_{hosp}(t)$  as:



$$X_{hosp}(t) := \sum_i \left( I_{H_R^*}^i(t) + I_{H_D^*}^i(t) + I_{ICU_{pre}^*}^i(t) + I_{W_D^*}^i(t) + I_{W_R^*}^i(t) \right) \quad (166)$$

391 Which was related to the observed daily general bed-occupancy via a reporting distribution:

$$Y_{hosp}(t) \sim \text{NegBinom}(X_{hosp}(t), \kappa_{hosp}) \quad (167)$$

392 with  $\kappa_{hosp} = 2$  as above.

393

394 Similarly, the model predicted ICU bed occupancy by confirmed COVID-19 cases,  $X_{ICU}(t)$   
395 as:

$$X_{ICU}(t) := \sum_i \left( I_{ICU_{W_R^*}}^i(t) + I_{ICU_{W_D^*}}^i(t) + I_{ICU_{D^*}}^i(t) \right) \quad (168)$$

396 Which was related to the observed daily ICU bed-occupancy via a reporting distribution:

397

$$Y_{ICU}(t) \sim \text{NegBinom}(X_{ICU}(t), \kappa_{ICU}) \quad (169)$$

398

399 with  $\kappa_{ICU} = 2$ .

#### 400 1.7.4 Hospital and care homes COVID-19 deaths

401 The reported number of daily COVID-19 deaths in hospitals,  $Y_{hosp_D}(t)$  was considered as  
402 the observed realisation of an underlying hidden Markov process,  $X_{hosp_D}(t)$ , defined as:

$$X_{hosp_D}(t) := \sum_i \left( d_{H_{D,D}}^i + d_{H_{D^*,D}}^i + d_{ICU_{D,D}}^i + d_{ICU_{D^*,D}}^i + d_{W_{D,D}}^i + d_{W_{D^*,D}}^i \right) \quad (170)$$

403

404 Which was related to the data via a reporting distribution:

$$Y_{hosp_D}(t) \sim \text{NegBinom}(X_{hosp_D}(t), \kappa_{hosp_D}) \quad (171)$$

405 with  $\kappa_{hosp_D} = 2$ .

406 Similarly, we represented the reported number of daily COVID-19 deaths in care homes,  
407  $Y_{G_D}(t)$ , as the observed realisations of an underlying hidden Markov process,  $X_{G_D}(t)$ , defined  
408 as:

$$X_{G_D}(t) := d_{G_D,D}^{CHR} \quad (172)$$

409 Which was related to the data via a reporting distribution:

$$Y_{G_D}(t) \sim \text{NegBinom}(X_{G_D}(t), \kappa_{G_D}) \quad (173)$$

410 with  $\kappa_{G_D} = 2$ .

411

#### 412 1.7.5 Serosurveys

413 We model serological testing of all individuals aged 15-65, and define the resulting number  
414 of seropositive and seronegative individuals (were all individuals aged 15-65 to be tested),  
415 as:

$$X_{sero_{pos}}(t) := \sum_{i=[15,20]}^{[60,65]} T_{sero_{pos}}^i(t) \quad (174)$$

416

$$X_{sero_{neg}}(t) := \left( \sum_{i=[15,20]}^{[60,65]} N^i \right) - X_{sero_{pos}}(t) \quad (175)$$

417 We compared the observed number of seropositive results,  $Y_{sero_{pos}}(t)$ , with that predicted by  
 418 our model, allowing for i) the sample size of each serological survey,  $Y_{sero_{pos}}(t)$  and ii)  
 419 imperfect sensitivity ( $p_{sero_{sens}}$ ) and specificity ( $p_{sero_{spec}}$ ) of the serological assay:

$$Y_{sero_{pos}}(t) \sim \text{Binom} \left( Y_{sero_{test}}(t), \omega_{sero_{pos}}(t) \right) \quad (176)$$

420 Where:

$$\omega_{sero_{pos}}(t) := \frac{p_{sero_{sens}} X_{sero_{pos}}(t) + (1 - p_{sero_{spec}}) X_{sero_{neg}}(t)}{X_{sero_{pos}}(t) + X_{sero_{neg}}(t)} \quad (177)$$

421

### 422 1.7.6 PCR testing

423 As described in the data section (1.1), we fitted the model to PCR testing data from two  
 424 separate sources:

- 425 • pillar 2: the government testing programme, which recommends that individuals with  
 426 COVID-19 symptoms are tested (34),
- 427 • the REACT-1 study, which aims to quantify the prevalence of SARS-CoV-2 in a  
 428 random sample of the England population on an ongoing basis (35).

429

430 We only use Pillar 2 PCR test results for individuals aged 25 and over (we assume this  
 431 includes all care home workers and residents). We assume that individuals who get tested  
 432 through Pillar 2 PCR testing are either newly symptomatic SARS-CoV-2 cases (who will test  
 433 positive):

$$X_{P2_{pos}}(t) := \sum_{i=[25,30]}^{CHW} d_{E,IC}^i \quad (178)$$

434

435 or non-SARS-CoV-2 cases who have symptoms consistent with COVID-19 (who will test  
 436 negative):

$$X_{P2_{neg}}(t) := p_{NC} \left( \left( \sum_{i=[25,30]}^{CHW} N^i \right) - X_{P2_{pos}}(t) \right) \quad (179)$$

437

438 where  $p_{NC}$  is the probability of non SARS-CoV-2 cases having symptoms consistent with  
 439 COVID-19 leading them to seek a PCR test.

440

441 We compared the observed number of positive PCR tests,  $Y_{P2_{pos}}(t)$  with that predicted by  
 442 our model, accounting for the number of PCR tests conducted each day under pillar 2,  
 443  $Y_{P2_{test}}(t)$ , by calculating the probability of a positive PCR result (assuming perfect sensitivity  
 444 and specificity of the PCR test):

$$\omega_{P2_{pos}}(t) := \left( X_{P2_{pos}}(t) \right) / \left( X_{P2_{pos}}(t) + X_{P2_{neg}}(t) \right) \quad (180)$$

445

446 People may seek PCR tests for many reasons and thus the pillar 2 data are subject to  
 447 competing biases. We therefore allowed for an over-dispersion parameter  $\rho_{P2_{test}}$ , which we  
 448 fitted separately for each region in the modelling framework:

$$Y_{P2_{pos}}(t) \sim \text{BetaBinom} \left( Y_{P2_{test}}(t), \omega_{P2_{pos}}(t), \rho_{P2_{test}} \right) \quad (181)$$

449

450 We incorporated the REACT-1 PCR testing data into the likelihood analogously to the  
 451 serology data, by considering the model-predicted number of PCR-positives  $X_{R1_{pos}}(t)$  and  
 452 PCR-negatives  $X_{R1_{neg}}(t)$ , were all individuals aged over five and not resident in a care home  
 453 to be tested:

454

$$X_{R1_{pos}}(t) := \sum_{i=[5,10), \dots, [80+), CHW} T_{PCR_{pos}}^i(t) \quad (182)$$

$$X_{R1_{neg}}(t) := \sum_{i=[5,10), \dots, [80+), CHW} N^i(t) - X_{R1_{pos}}(t) \quad (183)$$

455

456 We compared the daily number of positive results observed in REACT-1,  $Y_{R1_{pos}}(t)$ , given the  
 457 number of people tested on that day,  $Y_{R1_{test}}(t)$ , to our model predictions, by calculating the  
 458 probability of a positive result, assuming perfect sensitivity and specificity of the REACT-1  
 459 assay:

$$\omega_{R1_{pos}}(t) := \left( X_{R1_{pos}}(t) \right) / \left( X_{R1_{pos}}(t) + X_{R1_{neg}}(t) \right) \quad (184)$$

460

$$Y_{R1_{pos}}(t) \sim \text{Binom} \left( Y_{R1_{test}}(t), \omega_{R1_{pos}}(t) \right) \quad (185)$$

461

462 The overall likelihood function was then calculated as the product of the likelihoods of the  
 463 individual observations.

464

## 465 1.8 Bayesian inference and model fitting

466 A closed-form expression of the likelihood of the observed data given the model and its  
 467 parameters was not analytically tractable, so we used particle filtering methods to obtain an  
 468 unbiased estimate of the likelihood which can be efficiently sampled from (36). Where  
 469 appropriate, we used estimates from the literature to set model parameters at fixed values.  
 470 We limited the parameters being inferred to just those with particular epidemiological  
 471 interest, or with large uncertainty in existing literature.

472

473 The model was fitted independently to each NHS region. For each NHS region, we aimed to  
 474 infer the values of 26 model parameters:

- 475 • the local epidemic start-date,  $t_0$ ;

- 476 • thirteen transmission rates at different time points  $\beta_1, \dots, \beta_{12}$ ;
- 477 • three parameters governing transmission to and within care homes
- 478  $m_{CHW}, m_{CHR}, \epsilon$ ;
- 479 • the probability of symptomatic individuals developing serious disease
- 480 requiring hospitalisation,  $p_H^{max}$ , for the group with the largest probability;
- 481 • the probability of a care home resident dying in a care home if they have
- 482 severe disease requiring hospitalisation,  $p_{GD}^{CHR}$ ;
- 483 • the probability, at the start of the pandemic, of a patient being admitted to ICU
- 484 after hospitalisation,  $p_{ICU}^{max}$ , for the group with the largest probability;
- 485 • the probabilities, at the start of the pandemic, of dying in a hospital general
- 486 ward,  $p_{HD}^{max}$ , in the ICU,  $p_{ICUD}^{max}$ , and in a stepdown ward following ICU,  $p_{WD}^{max}$ ,
- 487 for the groups with the largest probability;
- 488 • the multiplier for hospital mortality after improvement in care,  $\mu_H$ ;
- 489 • the multiplier for probability of admission to ICU after improvement in care,
- 490  $\mu_{ICU}$ ;
- 491 • the daily proportion  $p_{NC}$ , of the population seeking to get tested for an infection
- 492 of SARS-Cov-2 following COVID-19 like symptoms and the overdispersion of
- 493 the corresponding observation distribution  $\rho_{P2test}$ .

494

495 We used particle Monte Carlo Markov Chain (pMCMC) methods (37), implementing a  
 496 particle marginal Metropolis-Hastings algorithm with a bootstrap particle filter (38) with 96  
 497 particles (for sufficient variance in likelihood and a convenient multiple of number of  
 498 available CPU cores for efficiency), to obtain a sample from the posterior distribution of the  
 499 model parameters given the observed data. If the expected values of count distributions are  
 500 zero when observed values are non-zero, this results in particles of zero weight, which can  
 501 lead to the particle filter estimating the marginal likelihood to be 0. Therefore, to get a small  
 502 but non-zero weight for each particle at every observation, within our particle filter likelihood  
 503 we add a small amount of noise (exponentially distributed with mean  $10^{-6}$ ) to count values  
 504 from the model.

505

506 Within our particle filter we add small amounts of exponentially-distributed noise (with mean  
 507  $10^{-6}$ ) to model outputs prior to calculating likelihood weights to avoid particles of zero  
 508 weight, instead resulting in small but non-zero weights.

509 We implemented our model and parameter inference in an R package, *sircovid* (39),  
 510 available at <https://mrc-ide.github.io/sircovid>, which uses two further R packages, *dust* to run  
 511 the model in efficient compiled code and *mcstate* to implement the pMCMC sampler using  
 512 Metropolis-Hastings sampling (40).

513 At each iteration, the sampler proposes an update to the joint distribution of parameters.  
 514 These proposals are generated from multivariate Gaussian densities centred on the current  
 515 parameter values, and with a covariance structure chosen to facilitate efficient mixing of the  
 516 Markov chain. We specified reflecting boundaries for the proposal kernel to ensure that the  
 517 proposed parameters are both epidemiologically and mathematically plausible and retain  
 518 symmetry in the proposals.

519 For each regional fit, eight parallel chains of the pMCMC were run for 11,000 iterations, with  
 520 the first 1,000 discarded as burn-in, and a 1/80 thinning. We assessed convergence visually.

521

## 522 1.9 Prior distributions and parameter calibration

### 523 1.9.1 Risk of hospital admission

524 In our Bayesian inference framework, we estimate  $p_H^{max}$ , the probability of hospital  
525 admission for symptomatic cases in the group (across all ages and CHW and CHR) with the  
526 largest probability of hospital admission. However, we fix the relative probability of hospital  
527 admission for the other age groups,  $\psi_H^i$ , defined so that  $p_H^i = p_H^{max} \psi_H^i$ , with  $\psi_H^i = 1$  in the  
528 group with largest probability of hospital admission.

529 In this section we explain how the values of  $\psi_H^i$  were chosen. We used two sources of  
530 information, an individual-level and an aggregated dataset. On the one hand, the COVID-19  
531 Hospitalisation in England Surveillance System (CHES) is a daily, confidential line list  
532 containing highly detailed information on patients admitted to hospital with confirmed  
533 COVID-19 (see following section 1.9.2 for further details). On the other hand, the  
534 Government's Coronavirus Dashboard is an aggregated, publicly available situation report  
535 updated daily. Amongst other data, it provides updates on the number of daily admissions  
536 and hospital occupancy by devolved nation and, for England, by NHS region. We found the  
537 demography of hospitalisation in CHES to be biased toward older patients compared to  
538 Dashboard data (Figure S3). We thus undertook a two-step approach to infer the  
539 demographic composition of COVID-19 hospitalisations across England.

540 Firstly, we derived an initial approximation of  $\psi_H^i$  by dividing the total number of hospital  
541 admissions for age group  $i$  in CHES over the total number of positive PCR tests (Pillar 2)  
542 for  $i$ . Both data sources were censored to include patients admitted to hospital or with a  
543 specimen data (i.e. the date the test was taken), respectively, between March 1 and  
544 December 2, 2020. We ran our full inference framework using this initial approximation  
545 for  $\psi_H^i$  and observed its fit to the demographic composition of admissions from the data.


546 As a second step, we refined our initial approximations of  $\psi_H^i$  over a series of iterations of  
547 our inference framework, by drawing the modelled ( $p_{H_{Model}}^i$ ) and observed ( $p_{H_{Dashboard}}^i$ )  
548 proportion of admissions for each age group (i.e. admissions in age group  $i$  divided by all  
549 admissions) and using it to derive a re-scaling factor for a new proposal for  $\psi_H^i$  as follows:

550

$$New \psi_H^i = Initial \psi_H^i * \frac{p_{H_{Dashboard}}^i}{p_{H_{Model}}^i} \quad (186)$$

551

552 This process was repeated to obtain a close approximation to the observed proportion of  
553 admissions by age and region (Figure S3). A key strength of our approach is that we did not  
554 overfitted demography by individual regions. Rather, by assuming  $\psi_H^i$  to be independent of  
555 geographic region, we allowed our inference framework to derive the number of admissions  
556 for each five-year age band  $i$  solely based on  $\psi_H^i$ , the demographic composition of the NHS  
557 region and inferred epidemic parameters, such as  $R_t$ .



558


559 *Figure S 3: Proportion of admissions by age. a) Comparison of model outputs to data from the*  
 560 *Government's Coronavirus Dashboard, aggregated to five broad age categories. b) Age spline fitted*  
 561 *(red) to Government's Coronavirus Dashboard, with age categories disaggregated to five-year bands.*  
 562 *The fitted spline (red) was used as input parameters for the probability of hospitalisation by age.*

563

### 564 1.9.2 Severity and hospital progression

565 We also performed extensive preliminary analysis to inform the age-structure of progression  
 566 parameters within hospital. Data from the COVID-19 Hospitalisation in England Surveillance  
 567 System (CHES) were used to fit a simple model of patient clinical progression in hospital.  
 568 The model structure was designed to mirror the within-hospital component of the wider  
 569 mechanistic transmission model, but without the complexities arising from unknown  
 570 admission dates and with greater detail on trends with age (Figure S 4).

571



572

573 *Figure S 4: Directed Acyclic Graph of the hospital pathways fitted to CHES data, which mirror the*  
 574 *model structure described in Figure S 2, but with all parameters varying with age and not over time.*

575

576 CHES data consists of a line list of daily individual patient-level data on COVID-19 infection  
 577 in persons requiring hospitalisation, including demographic and clinical information on  
 578 severity and outcomes. Data were filtered to patients admitted between 18<sup>th</sup> March and 31<sup>st</sup>  
 579 May 2020 (inclusive), with subsequent progression events possible up until 25<sup>th</sup> Nov 2020.  
 580 This gave >5 months for outcomes to complete, and hence justified filtering to patients with  
 581 resolved outcomes only. The length of stay in each state was taken as the difference  
 582 between the registered dates of entering and leaving each hospital ward. Lengths of stay  
 583 were assumed to follow Erlang distributions, as in the wider model, with a distinct mean and  
 584 shape parameter for each state. Specifically, the probability of being in state  $X \in$   
 585  $\{pre, H_D, H_R, ICU_D, ICU_{W_R}, ICU_{W_D}, W_R, W_D\}$  for  $n \in \mathbb{N}_0$  days was taken as the integral over day  
 586  $n$  of the Erlang distribution with mean  $m_X$  and shape  $s_X$ :

587

$$\Pr(\text{in state } X \text{ for } n \text{ days}) = \int_n^{n+1} \frac{\left(\frac{s_X}{m_X}\right)^{s_X} t^{s_X-1} e^{-\frac{s_X t}{m_X}}}{(s_X - 1)!} dt. \quad (187)$$

588

589 For a patient of age  $a$ , this was combined with the probability of their path through the  
 590 hospital progression model, taken as the product of the individual transition probabilities at  
 591 each bifurcation, i.e. values taken from  $p_Z(a)$  for  $Z \in \{ICU, H_D, ICU_D, W_D\}$ . Transition  
 592 probabilities were modelled as functions of age using logistic-transformed cubic splines.  
 593 Knots were defined at coordinates  $[x^i, y_Z^i]$ , where  $x^i$  values were fixed at  
 594  $\{0, 20, 40, 60, 80, 100, 120\}$  and  $y_Z^i$  were free parameters to be estimated. The complete  
 595 spline,  $y_Z(a)$  for  $a \in 0: 120$ , was obtained from these knots using standard expressions for  
 596 cubic spline interpolation. Finally, transition probabilities were obtained from the raw  $y_Z(a)$   
 597 values using the logistic transformation:  $p_Z(a) = 1/(1 + e^{-y_Z(a)})$ .

598 In total there were 44 free parameters in the within-hospital progression model: 8 mean  
 599 length of stay parameters, 8 length of stay shape parameters and  $4 \times 7$  transition probability  
 600 spline nodes (Figure S 4, Table S 4).

601

602 *Table S 4: Descriptions of all states and transitions in the simplified hospital progression model fitted*  
 603 *to CHESS data.*

State ( $X$ )	Description
$pre$	General admission before step-up to ICU
$H_D$	General ward before death in general ward
$H_R$	General ward before discharge from general ward
$ICU_D$	ICU before death in ICU
$ICU_{W_D}$	ICU before step-down and eventual death in step-down care
$ICU_{W_R}$	ICU before step-down and eventual discharge from step-down care
$W_D$	Step-down (general) ward before death
$W_R$	Step-down (general) ward before discharge
Transition ( $Z$ )	Description
$ICU$	Admission to ICU from general ward
$H_D$	Death in general ward
$ICU_D$	Death in ICU
$W_D$	Death in step-down care

604

605 All parameters of the hospital progression model were given priors (Table S 5) and  
 606 estimated within a Bayesian framework. All length of stay parameters were given uniform  
 607 priors over a plausible range of values. For transition probabilities, the first spline node  $y_2^1$   
 608 was given a prior that corresponded to a uniform distribution after logistic transformation,  
 609 and subsequent spline nodes were given a multivariate normal prior to apply a smoothing  
 610 constraint to the spline. Parameters were estimated jointly via MCMC using the custom  
 611 package *markovid* v1.5.0 (41), which uses the random-walk Metropolis-Hastings algorithm to  
 612 draw from the joint posterior distribution. MCMC was run for 1000 burn-in iterations and  
 613 100,000 sampling iterations replicated over 10 independent chains. Convergence was  
 614 assessed via the Gelman-Rubin diagnostic (all parameters had potential scale reduction  
 615 factor  $< 1.1$ ) and sampling sufficiency was assessed by visualising posterior distributions and  
 616 by effective sample size (ESS) calculations (all parameters had ESS  $> 100,000$ ).

617 *Table S 5: Priors on all length of stay distributions and transition probability splines.  $Uniform_{cont}(a, b)$*   
 618 *denotes the continuous uniform distribution, and  $Uniform_{disc}(a, b)$  the discrete uniform distribution*  
 619 *between  $a$  and  $b$  (inclusive).*

Parameter	Description	Prior
$m_X = \frac{1}{\gamma_X}$	Mean of Erlang length of stay distribution	$m_X \sim Uniform_{cont}(0, 20)$



$k_X$	Shape parameter of Erlang length of stay distribution	$k_X \sim \text{Uniform}_{\text{disc}}(1,10)$
$y_Z^1$	First spline node of (transformed) transition probability	$f(y_Z^1) \propto \frac{e^{-y_Z^1}}{(1+e^{-y_Z^1})^2}$ , for $y_Z^1 \in (-10, 10)$
$y_Z^j$ for $j \in 2:7$	Subsequent spline nodes of (transformed) transition probability	$y_Z^j \sim \text{Normal}(y_Z^{j-1}, 0.25)$

620

621 Parameter estimates (posterior medians) were passed to the wider mechanistic transmission  
622 model as fixed values (Figure S 5). For transition probabilities, the full age-spline (Figure 3,  
623 main text) was aggregated to 5-year age groups and normalised by the largest value to  
624 define the relative risk with age. The absolute risk in the mechanistic transmission model  
625 was obtained by multiplying the relative risk by region-specific scaling factors that were fitted  
626 as free parameters in the pMCMC. Hence, the preliminary analysis of CHES data was  
627 used to inform trends of severity with age, but not the absolute probability of progression  
628 through the hospital states, which was informed by the Government's Coronavirus  
629 Dashboard data.


630 For the wider mechanistic transmission model, we used Beta distributions for the priors of  
631 the various fitted probabilities regarding hospitalisation. The priors for  $p_{ICU}^{max}$ ,  $p_{H_D}^{max}$ ,  $p_{ICU_D}^{max}$  and  
632  $p_{W_D}^{max}$  were all informed by the fitting to CHES data by taking the median fitted value for the  
633 prior mean, which we halve in the case of  $p_{ICU}^{max}$  to account for CHES being biased to more  
634 severe patients. The prior distributions are then calibrated so that the lower bound of the  
635 95% confidence interval is 0.1 lower than the prior mean. For  $p_H^{max}$  and  $p_{G_D}^{CHR}$ , we assume  
636 prior means of 0.75 and calibrate the prior so that the lower bound of the 95% confidence  
637 interval is 0.2 lower than the mean. For the multipliers for hospital mortality after  
638 improvement in care,  $\mu_H$ , and for probability of admission to ICU after improvement in care,  
639  $\mu_{ICU}$ , we used uninformative  $U[0,1]$  priors.

640

641

642

Length of stay in each hospital state



643  
644 *Figure S 5: Posterior 95% credible intervals of length of stay mean (left) and shape parameters (right).*

645

### 646 1.9.3 Serosurveys

647 To keep serology parameters consistent between all regions we used estimates from the  
648 literature to fix the parameters of the seroconversion process. An alternative would have  
649 been to use these estimates as priors within a hierarchical model where some parameters  
650 would be shared between regions, but this would be much more involved computationally.

651  
652 As described in section 1.3.2, the time to seroconversion from leaving the  $E^i$  compartment is  
653 modelled by an exponential distribution time spent in  $T_{sero\ pre}^i$  with a proportion  $p_{sero\ pos}$   
654 ultimately seroconverting and moving to  $T_{sero\ pos}^i$  and the remaining staying negative and  
655 moving to  $T_{sero\ neg}^i$ .

656

657 We fixed  $p_{sero\ pos}$  to 0.85 based on the estimate of 85% of infections becoming detectably  
658 seropositive with the EUROIMMUN assay used in the NHSBT serological surveys (42). The  
659 specificity of the serology test  $p_{sero\ spec}$  is fixed to 0.99 also from (42). Finally, the sensitivity of  
660 serology test  $p_{sero\ sens}$  is assumed to be 1 as it is non-distinguishable from the time varying  
661 seroconversion process (Table S7).

662

### 663 1.9.4 PCR positivity

664 As for other compartments, we modelled the duration of SARS-CoV-2 PCR-positivity after  
665 symptom onset using an Erlang distribution  $\tau \sim \text{Erlang}(k, \gamma)$ , with  $k$  successive compartments  
666 and a total mean time spent of  $\frac{k}{\gamma}$  and variance  $\frac{k}{\gamma^2}$ .

667 We estimated the parameters of this distribution from Omar et al. (16), which reported the  
668 cumulative distribution of duration of PCR positivity in 523 individuals with mild COVID-19  
669 disease in home quarantine in a German region. We performed a survival analysis using a  
670 gamma-accelerated failure time model fitted to their data, from which we estimated the  
671 mean and variance of the time from symptom onset to PCR negativity. This was used to  
672 derive values of  $k$  and  $\gamma$  shown in Table S 2.

### 673 1.9.5 Local start date of the epidemic

674 The start date of the epidemic for each region is assumed to have a uniform prior on the  
675 dates from 1<sup>st</sup> January 2020 to 15<sup>th</sup> March 2020, inclusive – with the latter date  
676 corresponding to the last date before the data begin.

677           1.9.6 *Time-varying transmission rates*

678 We set priors for the transmission rates  $\beta_1, \dots, \beta_{12}$  to reflect a Gamma distribution for the  
679 reproduction number  $R_t$  with a reasonable 95% confidence interval a priori. To obtain a prior  
680 for the corresponding  $\beta_k$ , we then scale by a factor of 0.0241 (given other parameter values,  
681  $\beta_k = 0.0241$  would correspond approximately to  $R_t = 1$ ). The 95% ranges for  $R_0$  we used  
682 are (i) (2.5, 3.5) at the onset of the epidemic (corresponding to  $\beta_1$ ); and then  $R_t$  (ii) (0.4, 3.5)  
683 at announcement of the first lockdown (corresponding to  $\beta_2$ ); and (iii) (0.4, 3) from the  
684 implementation of the first lockdown onwards (corresponding to  $\beta_3, \dots, \beta_{12}$ ). The values are  
685 consistent with the values of the COMIX study (43).

686           1.9.7 *Transmission within care homes*

687 For the transmission between care home workers and residents,  $m_{CHW}$ , and transmission  
688 among care home residents,  $m_{CHR}$ , we used a prior distributions reflecting that these are  
689 person-to-person infectious contact rates and thus should be scaled according to regional  
690 care home demography. We then used a Gamma distribution with shape 5 and mean  $\frac{0.1}{N^{CHR}}$   
691 for both of these parameters (recall that we assume there is a 1-to-1 ratio of care home  
692 workers to residents in each region, so  $N^{CHW} = N^{CHR}$ ).

693 For the parameter governing the reduction in contacts between the general population and  
694 care home residents,  $\epsilon$ , we used an uninformative  $U[0,1]$  prior.

695           1.9.8 *Parameters relating to Pillar 2 testing*

696 For both the parameters  $p_{NC}$  and  $\rho_{P2_{test}}$ , we used uninformative  $U[0,1]$  priors.

697 Table S 6: Inferred model parameter notations, prior and posterior distributions. Note that  $\Gamma(a, b)$  here refers to a Gamma distribution with shape  $a$  and scale  
 698  $b$  (such that the mean is  $ab$ ), and  $B(a, b)$  refers to a Beta distribution with shape parameters  $a$  and  $b$  (such that the mean is  $a/(a + b)$ ).

699

	Description	Group scaling	Prior	Mean (95% CI)	Posterior NW**	Mean (95% CrI) NEY	MID	EE	LON	SW	SE
$t_0$	Start date of regional outbreak (dd/mm/2020)	-	$U[01/01, 15/03]$	-	29-01 (13/01, 07/02)	03-02 (29/01, 09/02)	24-01 (12/01, 02/02)	06-02 (30/01, 14/02)	08-01 (02/01, 20/01)	12-02 (09/02, 17/02)	27-01 (20/01, 04/02)
<b>Transmission rate (pp)</b>											
$\beta(t)$	$\beta_1$	-	$\Gamma(136, 0.0006)$	0.07 (0.06, 0.08)	0.08 (0.06, 0.09)	0.08 (0.07, 0.09)	0.08 (0.07, 0.09)	0.08 (0.08, 0.09)	0.06 (0.06, 0.07)	0.09 (0.08, 0.09)	0.08 (0.07, 0.09)
	$\beta_2$	-	$\Gamma(21.9, 0.0026)$	0.06 (0.04, 0.08)	0.09 (0.06, 0.11)	0.08 (0.05, 0.1)	0.07 (0.05, 0.09)	0.06 (0.04, 0.07)	0.04 (0.03, 0.06)	0.07 (0.04, 0.09)	0.05 (0.03, 0.06)
	$\beta_3$	-	$\Gamma(4.25, 0.0079)$	0.03 (0.01, 0.07)	0.01 (0.01, 0.02)	0.02 (0.02, 0.02)	0.01 (0.01, 0.01)	0.02 (0.02, 0.02)	0.01 (0.01, 0.01)	0.02 (0.01, 0.02)	0.01 (0.01, 0.01)
	$\beta_4$	-	$\Gamma(4.25, 0.0079)$	0.03 (0.01, 0.07)	0.02 (0.02, 0.02)	0.02 (0.01, 0.02)	0.02 (0.02, 0.02)	0.02 (0.02, 0.02)	0.02 (0.02, 0.02)	0.02 (0.02, 0.02)	0.02 (0.01, 0.02)
	$\beta_5$	-	$\Gamma(4.25, 0.0079)$	0.03 (0.01, 0.07)	0.02 (0.02, 0.02)	0.02 (0.02, 0.03)	0.02 (0.02, 0.02)	0.02 (0.02, 0.02)	0.02 (0.02, 0.03)	0.02 (0.01, 0.02)	0.02 (0.02, 0.02)
	$\beta_6$	-	$\Gamma(4.25, 0.0079)$	0.03 (0.01, 0.07)	0.02 (0.02, 0.03)	0.02 (0.01, 0.02)	0.02 (0.01, 0.02)	0.02 (0.02, 0.02)	0.02 (0.02, 0.03)	0.02 (0.02, 0.03)	0.02 (0.02, 0.02)
	$\beta_7$	-	$\Gamma(4.25, 0.0079)$	0.03 (0.01, 0.07)	0.02 (0.02, 0.03)	0.02 (0.02, 0.03)	0.02 (0.02, 0.03)	0.02 (0.02, 0.02)	0.03 (0.02, 0.03)	0.02 (0.02, 0.03)	0.02 (0.02, 0.03)
	$\beta_8$	-	$\Gamma(4.25, 0.0079)$	0.03 (0.01, 0.07)	0.05 (0.04, 0.05)	0.04 (0.04, 0.05)	0.05 (0.04, 0.05)	0.04 (0.03, 0.04)	0.04 (0.04, 0.05)	0.03 (0.02, 0.04)	0.04 (0.03, 0.05)
	$\beta_9$	-	$\Gamma(4.25, 0.0079)$	0.03 (0.01, 0.07)	0.04 (0.04, 0.05)	0.04 (0.04, 0.04)	0.04 (0.03, 0.04)	0.04 (0.03, 0.04)	0.04 (0.03, 0.04)	0.04 (0.04, 0.05)	0.03 (0.03, 0.04)
	$\beta_{10}$	-	$\Gamma(4.25, 0.0079)$	0.03 (0.01, 0.07)	0.03 (0.03, 0.03)	0.03 (0.03, 0.04)	0.04 (0.04, 0.04)	0.04 (0.03, 0.04)	0.04 (0.04, 0.04)	0.04 (0.03, 0.04)	0.04 (0.04, 0.04)
	$\beta_{11}$	-	$\Gamma(4.25, 0.0079)$	0.03 (0.01, 0.07)	0.02 (0.02, 0.02)	0.03 (0.02, 0.03)	0.03 (0.02, 0.03)	0.03 (0.02, 0.03)	0.03 (0.02, 0.03)	0.03 (0.02, 0.03)	0.03 (0.03, 0.03)
	$\beta_{12}$	-	$\Gamma(4.25, 0.0079)$	0.03 (0.01, 0.07)	0.02 (0.02, 0.02)	0.02 (0.02, 0.02)	0.02 (0.02, 0.02)	0.02 (0.02, 0.03)	0.03 (0.03, 0.03)	0.02 (0.02, 0.02)	0.02 (0.02, 0.03)
$\epsilon$	Relative reduction in contacts between CHR and the general population	-	$U[0,1]$	0.5 (0.03, 0.98)	0.43 (0.03, 0.95)	0.75 (0.51, 0.98)	0.77 (0.37, 0.97)	0.79 (0.51, 0.96)	0.28 (0.03, 0.49)	0.82 (0.74, 0.91)	0.89 (0.77, 0.99)
$m_{CHW}$	Transmission rate between care home residents and staff	-	Regional Prior		$\Gamma(5, 4.3 \times 10^{-7})$ $2.2 \times 10^{-6}$ ( $7.0 \times 10^{-7}, 4.4 \times 10^{-6}$ )	$\Gamma(5, 3.7 \times 10^{-7})$ $1.8 \times 10^{-6}$ ( $5.9 \times 10^{-7}, 3.7 \times 10^{-6}$ )	$\Gamma(5, 2.9 \times 10^{-7})$ $1.5 \times 10^{-6}$ ( $4.7 \times 10^{-7}, 2.9 \times 10^{-6}$ )	$\Gamma(5, 5.2 \times 10^{-7})$ $2.6 \times 10^{-6}$ ( $8.4 \times 10^{-7}, 5.3 \times 10^{-6}$ )	$\Gamma(5, 7.6 \times 10^{-7})$ $3.8 \times 10^{-6}$ ( $1.2 \times 10^{-6}, 7.8 \times 10^{-6}$ )	$\Gamma(5, 4.9 \times 10^{-7})$ $2.5 \times 10^{-6}$ ( $8.0 \times 10^{-7}, 5.0 \times 10^{-6}$ )	$\Gamma(5, 3.1 \times 10^{-7})$ $1.6 \times 10^{-6}$ ( $5.1 \times 10^{-7}, 3.2 \times 10^{-6}$ )
			Posterior:		2.1e-06 (1.4e-06, 2.7e-06)	1.7e-06 (1.3e-06, 2.2e-06)	1.5e-06 (1.1e-06, 1.9e-06)	2.7e-06 (2.1e-06, 3.1e-06)	3.8e-06 (3.1e-06, 4.7e-06)	1.8e-06 (1.3e-06, 2.2e-06)	1.5e-06 (1.1e-06, 1.8e-06)

$m_{CHR}$	Transmission rate among care home residents	-	<i>Regional Prior</i>		$\Gamma(5, 4.3 \times 10^{-7})$ $2.2 \times 10^{-6}$ ( $7.0 \times 10^{-7}, 4.4 \times 10^{-6}$ )	$\Gamma(5, 3.7 \times 10^{-7})$ $1.8 \times 10^{-6}$ ( $5.9 \times 10^{-7}, 3.7 \times 10^{-6}$ )	$\Gamma(5, 2.9 \times 10^{-7})$ $1.5 \times 10^{-6}$ ( $4.7 \times 10^{-7}, 2.9 \times 10^{-6}$ )	$\Gamma(5, 5.2 \times 10^{-7})$ $2.6 \times 10^{-6}$ ( $8.4 \times 10^{-7}, 5.3 \times 10^{-6}$ )	$\Gamma(5, 7.6 \times 10^{-7})$ $3.8 \times 10^{-6}$ ( $1.2 \times 10^{-6}, 7.8 \times 10^{-6}$ )	$\Gamma(5, 4.9 \times 10^{-7})$ $2.5 \times 10^{-6}$ ( $8.0 \times 10^{-7}, 5.0 \times 10^{-6}$ )	$\Gamma(5, 3.1 \times 10^{-7})$ $1.6 \times 10^{-6}$ ( $5.1 \times 10^{-7}, 3.2 \times 10^{-6}$ )
			Posterior:		2.2e-06 (1e-06, 3.4e-06)	2.5e-06 (1.4e-06, 3.6e-06)	1.6e-06 (7e-07, 2.4e-06)	3.4e-06 (2.1e-06, 4.3e-06)	2.8e-06 (5e-07, 4.8e-06)	4.2e-06 (3.8e-06, 4.6e-06)	3.3e-06 (2.9e-06, 3.6e-06)
$p_H^{max}$	Probability of hospitalisation if symptomatic	$\psi_H^i$	B(15.8, 5.28)	0.75 (0.55, 0.91)	0.87 (0.8, 0.92)	0.9 (0.85, 0.94)	0.89 (0.83, 0.95)	0.78 (0.73, 0.84)	0.85 (0.79, 0.9)	0.86 (0.81, 0.93)	0.73 (0.68, 0.79)
$p_{CD}^{max}$	Probability of death in care home if requiring hospitalisation	$\psi_{CD}^i$	B(15.8, 5.28)	0.75 (0.55, 0.91)	0.66 (0.37, 0.85)	0.77 (0.64, 0.88)	0.53 (0.41, 0.69)	0.58 (0.52, 0.63)	0.66 (0.5, 0.91)	0.64 (0.6, 0.69)	0.36 (0.32, 0.43)
$p_{ICU}^{max}$	Probability of triage to ICU for new hospital admissions	$\psi_{ICU}^i$	B(13.9, 43.9)	0.24 (0.14, 0.36)	0.15 (0.11, 0.18)	0.15 (0.11, 0.18)	0.17 (0.13, 0.21)	0.25 (0.21, 0.31)	0.31 (0.26, 0.37)	0.12 (0.11, 0.13)	0.23 (0.2, 0.25)
$p_{HD}^{max}$	Initial probability of death for general inpatients	$\psi_{HD}^i$	B(42.1, 50.1)	0.46 (0.36, 0.56)	0.42 (0.35, 0.5)	0.46 (0.39, 0.53)	0.43 (0.38, 0.47)	0.47 (0.44, 0.51)	0.37 (0.32, 0.46)	0.5 (0.47, 0.53)	0.41 (0.35, 0.46)
$p_{ICUD}^{max}$	Initial probability of death for ICU inpatients	$\psi_{ICUD}^i$	B(60.2, 29.3)	0.67 (0.57, 0.77)	0.66 (0.6, 0.72)	0.71 (0.66, 0.77)	0.69 (0.58, 0.77)	0.69 (0.62, 0.75)	0.61 (0.51, 0.69)	0.71 (0.64, 0.77)	0.63 (0.54, 0.75)
$p_{WD}^{max}$	Initial probability of death for stepdown inpatients	$\psi_{WD}^i$	B(28.7, 52.1)	0.35 (0.25, 0.46)	0.35 (0.25, 0.46)	0.35 (0.3, 0.4)	0.36 (0.3, 0.5)	0.37 (0.3, 0.43)	0.34 (0.24, 0.43)	0.51 (0.44, 0.59)	0.37 (0.29, 0.45)
$\mu_{ICU}$	ICU admission multiplier after improvement in care	-	$U[0,1]$	0.5 (0.03, 0.98)	0.79 (0.59, 0.93)	0.76 (0.62, 0.93)	0.72 (0.56, 0.94)	0.51 (0.37, 0.64)	0.62 (0.51, 0.75)	0.83 (0.73, 0.99)	0.44 (0.3, 0.54)
$\mu_D$	Hospital mortality multiplier after improvement in care	-	$U[0,1]$	0.5 (0.03, 0.98)	0.58 (0.45, 0.69)	0.47 (0.41, 0.53)	0.49 (0.42, 0.61)	0.47 (0.42, 0.56)	0.32 (0.27, 0.38)	0.35 (0.28, 0.43)	0.53 (0.44, 0.63)
$p_{NC}$	Prevalence of non-COVID symptomatic leading to test	-	$U[0,1]$	0.5 (0.03, 0.98)	0.0031 (0.0029, 0.0033)	0.0022 (0.0021, 0.0024)	0.0025 (0.0023, 0.0027)	0.0028 (0.0026, 0.0031)	0.0028 (0.0027, 0.003)	0.0019 (0.0018, 0.002)	0.003 (0.0028, 0.0031)
$\rho_{P2_{test}}$	Overdispersion of PCR positivity	-	$U[0,1]$	0.5 (0.03, 0.98)	0.0052 (0.0042, 0.0062)	0.0076 (0.0064, 0.0086)	0.0072 (0.0058, 0.0088)	0.0033 (0.0029, 0.0037)	0.0026 (0.0021, 0.0031)	0.0091 (0.0079, 0.0103)	0.0032 (0.0027, 0.0037)

700 Age-specific scaling factors for each parameter are set out in Table S 8.\*\* Region codes: NW = North West, NEY = North East and Yorkshire, MID = Midlands, EE = East of England, LON = London,  
701 SW = South West, SE = South East. N.B. when the prior is region specific the prior is shown in the same columns as the posterior distributions

702

703

704 *Table S 7: Fixed model parameters (age / care home scaling factors are shown separately in Table S 8).*

Parameter	Description	Value	Source
$p_c$	Probability of developing symptoms after becoming infectious	0.6	Lavezzo et al. (44)
$p^*$	Probability of arriving at hospital with a confirmed diagnosis	0.25	NHS (45)
$1/\gamma_U$	Mean time to confirmation of diagnosis within hospital (days)	2 days	CHES (5)
$p_{sero_{pos}}$	Probability of seroconversion	0.85	Brazeau et al. (42)
$1/\gamma_{sero_{pos}}$	Mean time to seroconversion from infectiousness (days)	13	Benny et al. (17)
$p_{sero_{spec}}$	Specificity of serology test	0.99	Brazeau et al. (42)
$p_{sero_{sens}}$	Sensitivity of serology test	1	Assumption as non-distinguishable from time varying seroconversion

705

706

707 Table S 8: Age / care-home scaling factors


Population group	Age / care home -stratified scaling to probability of:					
	Hospitalisation if symptomatic ( $p_H$ )	Triage to ICU ( $p_{ICU}$ )	Death for general inpatients ( $p_{HD}$ )	Death in ICU ( $p_{ICUD}$ )	Death in stepdown ( $p_{WD}$ )	Death in the community ( $p_{GD}$ )
	$\psi_H^i$	$\psi_{ICU}^i$	$\psi_{HD}^i$	$\psi_{ICUD}^i$	$\psi_{WD}^i$	$\psi_{GD}^i$
<i>Age</i>						
[0, 5)	0.039	0.243	0.039	0.282	0.091	0
[5, 10)	0.001	0.289	0.037	0.286	0.083	0
[10, 15)	0.006	0.338	0.035	0.291	0.077	0
[15, 20)	0.009	0.389	0.035	0.299	0.074	0
[20, 25)	0.026	0.443	0.036	0.310	0.074	0
[25, 30)	0.040	0.503	0.039	0.328	0.076	0
[30, 35)	0.042	0.570	0.045	0.353	0.080	0
[35, 40)	0.045	0.653	0.055	0.390	0.086	0
[40, 45)	0.050	0.756	0.074	0.446	0.093	0
[45, 50)	0.074	0.866	0.107	0.520	0.102	0
[50, 55)	0.138	0.954	0.157	0.604	0.117	0
[55, 60)	0.198	<b>1.000</b>	0.238	0.705	0.148	0
[60, 65)	0.247	0.972	0.353	0.806	0.211	0
[65, 70)	0.414	0.854	0.502	0.899	0.332	0
[70, 75)	0.638	0.645	0.675	0.969	0.526	0
[75, 80)	<b>1.000</b>	0.402	0.832	<b>1.000</b>	0.753	0
80+	0.873	0.107	<b>1.000</b>	0.918	<b>1.000</b>	0
<i>Care home</i>						
CHW	0.104	0.784	0.134	0.519	0.114	0
CHR	0.873	0.107	<b>1.000</b>	0.918	<b>1.000</b>	<b>1</b>

708

709 **2 Supplementary Results**

710


711 **2.1 Model fitting**



712

713 *Figure S 6: Model fits by region to PCR positivity for individuals aged >25 years (top row) and PCR*  
714 *positivity from the REACT-1 study (bottom row). The points show the data and bars the 95% CI. The*  
715 *solid line the median model fit and the shaded area the 95% CrI.*

716




717

718 *Figure S 7: Model fits to daily hospital deaths (top row), daily care home deaths (second row), ICU*  
719 *bed occupancy (third row), general bed occupancy (fourth row), all hospital beds (fifth row), and all*  
720 *daily admissions (bottom row) by region (columns). The points show the data, the solid line the*  
721 *median model fit and the shaded area the 95% CrI.*

722



723 **2.2 Severity estimates**



724

725 *Figure S 8: Fits to CHES data broken down into one-year age bands. Blue ribbons show the 95%*  
 726 *Crl of the fitted spline, black circles and vertical segments give the raw mean and 95% CI from the*  
 727 *data (exact binomial).*


728

729 *Table S 9: Age-stratified estimates of disease severity (\*to 2sf, ^to 3dp)*

Age stratified estimate of:		
Age group	<i>Proportion of infections who were hospitalised*</i>	<i>Proportion of infections who died^</i>
[0, 5)	3.0% (2.8%, 3.2%)	0.031% (0.027%, 0.034%)
[5, 10)	0.26% (0.24%, 0.28%)	0.003% (0.002%, 0.003%)
[10, 15)	0.084% (0.078%, 0.089%)	0.001% (0.001%, 0.001%)
[15, 20)	0.042% (0.039%, 0.045%)	0.000% (0.000%, 0.001%)
[20, 25)	0.080% (0.075%, 0.085%)	0.001% (0.001%, 0.001%)
[25, 30)	0.26% (0.24%, 0.28%)	0.004% (0.003%, 0.004%)
[30, 35)	0.40% (0.37%, 0.42%)	0.006% (0.006%, 0.007%)
[35, 40)	0.63% (0.58%, 0.67%)	0.013% (0.011%, 0.014%)
[40, 45)	1.2% (1.1%, 1.2%)	0.031% (0.026%, 0.035%)
[45, 50)	1.9% (1.8%, 2.1%)	0.070% (0.061%, 0.080%)
[50, 55)	2.3% (2.2%, 2.5%)	0.116% (0.101%, 0.133%)
[55, 60)	4.0% (3.8%, 4.3%)	0.276% (0.242%, 0.315%)
[60, 65)	9.6% (8.9%, 10%)	0.867% (0.762%, 0.971%)
[65, 70)	10% (9.6%, 11%)	1.215% (1.070%, 1.352%)
[70, 75)	24% (22%, 26 %)	3.512% (3.083%, 3.900%)
[75, 80)	50% (46%, 53%)	8.430% (7.407%, 9.338%)
80+	50% (47%, 54%)	9.696% (8.501%, 10.640%)
Combined	20% (13%, 27%)	34.132% (28.020%, 41.359%)

730

Supplementary counterfactual analysis



732

733 *Figure S 9: Counterfactual intervention scenarios in each England NHS Region: Panel A1-7 impact of*  
 734 *locking down one-week earlier Panel B1-7 impact of locking down one week later; Panel C1-7 impact*  
 735 *of relaxing lockdown restrictions two weeks earlier. Panel D1-7 impact of relaxing lockdown*  
 736 *restrictions two weeks later; Panel E1-7 impact of 50% less contact between care home residents and*  
 737 *the general population; Panel F1-7 impact of 50% more contact between care home residents and the*  
 738 *general population.*

739

740

## References

- 741 1. Buitrago-Garcia D, Egli-Gany D, Counotte MJ, Hossmann S, Imeri H, Ipekci AM, et al.  
742 Occurrence and transmission potential of asymptomatic and presymptomatic SARS-  
743 CoV-2 infections: A living systematic review and meta-analysis. *PLoS Med.*  
744 2020;17(9):e1003346.
- 745 2. GOV.UK. Coronavirus (COVID-19) in the UK [Internet]. 2020 [cited 2020 Dec 3].  
746 Available from: <https://coronavirus.data.gov.uk/details/download>
- 747 3. Riley S, Walters CE, Wang H, Eales O, Ainslie KEC, Atchison C, et al. REACT-1  
748 round 7 updated report: regional heterogeneity in changes in prevalence of SARS-  
749 CoV-2 infection during the second national COVID-19 lockdown in England. *medRxiv.*  
750 2020 Dec 16;2020.12.15.20248244.
- 751 4. Public Health England. Sero-surveillance of COVID-19 - GOV.UK [Internet]. [cited  
752 2020 Dec 16]. Available from: [https://www.gov.uk/government/publications/national-](https://www.gov.uk/government/publications/national-covid-19-surveillance-reports/sero-surveillance-of-covid-19)  
753 [covid-19-surveillance-reports/sero-surveillance-of-covid-19](https://www.gov.uk/government/publications/national-covid-19-surveillance-reports/sero-surveillance-of-covid-19)
- 754 5. NHS Digital. SGSS and CHES data - NHS Digital [Internet]. [cited 2020 Dec 4].  
755 Available from: [https://digital.nhs.uk/about-nhs-digital/corporate-information-and-](https://digital.nhs.uk/about-nhs-digital/corporate-information-and-documents/directions-and-data-provision-notice/data-provision-notice-dpns/sgss-and-ches-data)  
756 [documents/directions-and-data-provision-notice/data-provision-notice-dpns/sgss-](https://digital.nhs.uk/about-nhs-digital/corporate-information-and-documents/directions-and-data-provision-notice/data-provision-notice-dpns/sgss-and-ches-data)  
757 [and-ches-data](https://digital.nhs.uk/about-nhs-digital/corporate-information-and-documents/directions-and-data-provision-notice/data-provision-notice-dpns/sgss-and-ches-data)
- 758 6. Office for National Statistics. Office for National Statistics [Internet]. [cited 2020 Dec  
759 16]. Available from: <https://www.ons.gov.uk/>
- 760 7. Care Quality Commission. [ARCHIVED CONTENT] UK Government Web Archive -  
761 The National Archives [Internet]. [cited 2020 Dec 16]. Available from:  
762 [https://webarchive.nationalarchives.gov.uk/20200605160439/https://www.cqc.org.uk/fi-](https://webarchive.nationalarchives.gov.uk/20200605160439/https://www.cqc.org.uk/files/cqc-care-directory-filters-1-june-2020)  
763 [les/cqc-care-directory-filters-1-june-2020](https://webarchive.nationalarchives.gov.uk/20200605160439/https://www.cqc.org.uk/files/cqc-care-directory-filters-1-june-2020)
- 764 8. GOV.UK. Care Homes Analysis Background. 2020.
- 765 9. Age UK. Later Life in the United Kingdom 2019 [Internet]. [cited 2020 Dec 16].  
766 Available from: [https://www.ageuk.org.uk/globalassets/age-uk/documents/reports-](https://www.ageuk.org.uk/globalassets/age-uk/documents/reports-and-publications/later_life_uk_factsheet.pdf)  
767 [and-publications/later\\_life\\_uk\\_factsheet.pdf](https://www.ageuk.org.uk/globalassets/age-uk/documents/reports-and-publications/later_life_uk_factsheet.pdf)
- 768 10. Mossong J, Hens N, Jit M, Beutels P, Auranen K, Mikolajczyk R, et al. Social contacts  
769 and mixing patterns relevant to the spread of infectious diseases. *PLoS Med.*  
770 2008;5(3):381–91.
- 771 11. Ladhani SN, Chow JY, Janarthanan R, Fok J, Crawley-Boevey E, Vusirikala A, et al.  
772 Investigation of SARS-CoV-2 outbreaks in six care homes in London, April 2020.  
773 *EClinicalMedicine.* 2020 Sep 1;26:100533.
- 774 12. Lauer SA, Grantz KH, Bi Q, Jones FK, Zheng Q, Meredith HR, et al. The incubation  
775 period of coronavirus disease 2019 (CoVID-19) from publicly reported confirmed  
776 cases: Estimation and application. *Ann Intern Med.* 2020;172(9):577–82.
- 777 13. Bi Q, Wu Y, Mei S, Ye C, Zou X, Zhang Z, et al. Epidemiology and transmission of  
778 COVID-19 in 391 cases and 1286 of their close contacts in Shenzhen, China: a  
779 retrospective cohort study. *Lancet Infect Dis.* 2020;(PG-).
- 780 14. Docherty AB, Harrison EM, Green CA, Hardwick HE, Pius R, Norman L, et al.  
781 Features of 20 133 UK patients in hospital with covid-19 using the ISARIC WHO  
782 Clinical Characterisation Protocol: Prospective observational cohort study. *BMJ.*  
783 2020;369(March):1–12.
- 784 15. Bernabeu-Wittel M, Ternero-Vega JE, Díaz-Jiménez P, Conde-Guzmán C, Nieto-  
785 Martín MD, Moreno-Gaviño L, et al. Death risk stratification in elderly patients with

- 786 covid-19. A comparative cohort study in nursing homes outbreaks. Arch Gerontol  
787 Geriatr. 2020;91:104240.
- 788 16. Omar S, Bartz C, Becker S, Basenach S, Pfeifer S, Trapp C, et al. Duration of SARS-  
789 CoV-2 RNA detection in COVID-19 patients in home isolation, Rhineland-Palatinate,  
790 Germany, 2020 - an interval-censored survival analysis. Eurosurveillance.  
791 2020;25(30):1–8.
- 792 17. Benny B, Amandine G, Kc P, Sarah H, Abby M, Caitlin C, et al. Quantifying antibody  
793 kinetics and RNA shedding during early-phase SARS-CoV-2 infection.
- 794 18. Funk S. Socialmixr: Social Mixing Matrices for Infectious Disease Modelling. The  
795 Comprehensive R Archive Network; 2018.
- 796 19. GOV.UK. Prime Minister’s statement on coronavirus (COVID-19): 12 March 2020 -  
797 GOV.UK [Internet]. [cited 2020 Dec 3]. Available from:  
798 [https://www.gov.uk/government/speeches/pm-statement-on-coronavirus-12-march-  
799 2020](https://www.gov.uk/government/speeches/pm-statement-on-coronavirus-12-march-2020)
- 800 20. GOV.UK. Prime Minister’s statement on coronavirus (COVID-19): 22 March 2020 -  
801 GOV.UK [Internet]. [cited 2020 Dec 3]. Available from:  
802 [https://www.gov.uk/government/speeches/pm-statement-on-coronavirus-22-march-  
803 2020](https://www.gov.uk/government/speeches/pm-statement-on-coronavirus-22-march-2020)
- 804 21. GOV.UK. Prime Minister’s statement on coronavirus (COVID-19): 25 March 2020 -  
805 GOV.UK [Internet]. [cited 2020 Dec 16]. Available from:  
806 [https://www.gov.uk/government/speeches/pm-statement-on-coronavirus-25-march-  
807 2020](https://www.gov.uk/government/speeches/pm-statement-on-coronavirus-25-march-2020)
- 808 22. GOV.UK. Prime Minister’s statement on coronavirus (COVID-19): 11 May 2020 -  
809 GOV.UK [Internet]. [cited 2020 Dec 16]. Available from:  
810 <https://www.gov.uk/government/speeches/pm-statement-on-coronavirus-11-may-2020>
- 811 23. GOV.UK. Prime Minister sets out timeline for retail to reopen in June - GOV.UK  
812 [Internet]. [cited 2020 Dec 16]. Available from:  
813 [https://www.gov.uk/government/news/prime-minister-sets-out-timeline-for-retail-to-  
814 reopen-in-june](https://www.gov.uk/government/news/prime-minister-sets-out-timeline-for-retail-to-reopen-in-june)
- 815 24. GOV.UK. Pubs, restaurants and hairdressers to reopen from 4 July - GOV.UK  
816 [Internet]. [cited 2020 Dec 16]. Available from:  
817 [https://www.gov.uk/government/news/pubs-restaurants-and-hairdressers-to-reopen-  
818 from-4-july](https://www.gov.uk/government/news/pubs-restaurants-and-hairdressers-to-reopen-from-4-july)
- 819 25. GOV.UK. Eat Out to Help Out launches today – with government paying half on  
820 restaurant bills - GOV.UK [Internet]. [cited 2020 Dec 16]. Available from:  
821 [https://www.gov.uk/government/news/eat-out-to-help-out-launches-today-with-  
822 government-paying-half-on-restaurant-bills](https://www.gov.uk/government/news/eat-out-to-help-out-launches-today-with-government-paying-half-on-restaurant-bills)
- 823 26. GOV.UK. Schools and colleges to reopen in full in September - GOV.UK [Internet].  
824 [cited 2020 Dec 16]. Available from: [https://www.gov.uk/government/news/schools-  
825 and-colleges-to-reopen-in-full-in-september](https://www.gov.uk/government/news/schools-and-colleges-to-reopen-in-full-in-september)
- 826 27. GOV.UK. Rule of six comes into effect to tackle coronavirus - GOV.UK [Internet].  
827 [cited 2020 Dec 7]. Available from: [https://www.gov.uk/government/news/rule-of-six-  
828 comes-into-effect-to-tackle-coronavirus](https://www.gov.uk/government/news/rule-of-six-comes-into-effect-to-tackle-coronavirus)
- 829 28. GOV.UK. Prime Minister announces new local COVID Alert Levels - GOV.UK  
830 [Internet]. [cited 2020 Dec 7]. Available from:  
831 [https://www.gov.uk/government/news/prime-minister-announces-new-local-covid-  
832 alert-levels](https://www.gov.uk/government/news/prime-minister-announces-new-local-covid-alert-levels)

- 833 29. GOV.UK. Prime Minister announces new national restrictions - GOV.UK [Internet].  
834 [cited 2020 Dec 7]. Available from: [https://www.gov.uk/government/news/prime-](https://www.gov.uk/government/news/prime-minister-announces-new-national-restrictions)  
835 [minister-announces-new-national-restrictions](https://www.gov.uk/government/news/prime-minister-announces-new-national-restrictions)
- 836 30. Funk S. socialmixr @ github.com.
- 837 31. The RECOVERY Collaborative Group. Dexamethasone in Hospitalized Patients with  
838 Covid-19 — Preliminary Report. *N Engl J Med.* 2020;1–11.
- 839 32. Diekmann O, Heesterbeek JAP, Metz JAJ. On the definition and the computation of  
840 the basic reproduction ratio  $R_0$  in models for infectious diseases in heterogeneous  
841 populations. *J Math Biol.* 1990;28(4):365–82.
- 842 33. Gillespie DT. Approximate accelerated stochastic simulation of chemically reacting  
843 systems. *J Chem Phys.* 2001;115(4):1716–33.
- 844 34. Department of Health and Social Care. COVID-19 testing data: methodology note.  
845 [www.gov.uk](http://www.gov.uk). 2020.
- 846 35. Martin IMC, Ison CA, Aanensen DM, Fenton KA, Spratt BG. Rapid Sequence-Based  
847 Identification of Gonococcal Transmission Clusters in a Large Metropolitan Area. *J*  
848 *Infect Dis.* 2004;189(8):1497–505.
- 849 36. Del Moral P, Doucet A, Jasra A. Sequential Monte Carlo samplers. *J R Stat Soc Ser B*  
850 *Stat Methodol.* 2006;68(3):411–36.
- 851 37. Andrieu C, Doucet A, Holenstein R. Particle Markov chain Monte Carlo methods. *J R*  
852 *Stat Soc Ser B Stat Methodol.* 2010;72(3):269–342.
- 853 38. Gordon NJ, Salmond DJ, Smith AFM. Novel approach to nonlinear/non-gaussian  
854 Bayesian state estimation. *IEE Proceedings, Part F Radar Signal Process.*  
855 1993;140(2):107–13.
- 856 39. Baguelin M, Knock E, Whittles LK, FitzJohn R, Lees J. sircovid. 2020.
- 857 40. Knock ES, Whittles LK, Perez-Guzman PN, Bhatia S, Guntoro F, Watson OJ, et al.  
858 Reproducible parallel inference and simulation of stochastic state space models using  
859 odin, dust, and mcstate. *Wellcome Open Res.* 2020 Dec 11;5:288.
- 860 41. Verity R, FitzJohn R. mrc-ide/markovid at version1.5 [Internet]. [cited 2020 Dec 4].  
861 Available from: <https://github.com/mrc-ide/markovid/tree/version1.5>
- 862 42. Brazeau NF, Verity R, Jenks S, Fu H, Whittaker C, Winskill P, et al. Infection Fatality  
863 Ratio: Estimates from Seroprevalence.
- 864 43. Jarvis CI, Van Zandvoort K, Gimma A, Prem K, Auzenbergs M, O’Reilly K, et al.  
865 Quantifying the impact of physical distance measures on the transmission of COVID-  
866 19 in the UK. *BMC Med.* 2020;18(1):1–10.
- 867 44. Lavezzo E, Franchin E, Ciavarella C, Cuomo-Dannenburg G, Barzon L, Del Vecchio  
868 C, et al. Suppression of a SARS-CoV-2 outbreak in the Italian municipality of Vo’.  
869 *Nature.* 2020;
- 870 45. NHS England and NHS Improvement. Statistics » COVID-19 Hospital Activity  
871 [Internet]. [cited 2020 Dec 17]. Available from:  
872 <https://www.england.nhs.uk/statistics/statistical-work-areas/covid-19-hospital-activity/>  
873